WO2008051826A2 - Purines as pkc-theta inhibitors - Google Patents

Purines as pkc-theta inhibitors Download PDF

Info

Publication number
WO2008051826A2
WO2008051826A2 PCT/US2007/081899 US2007081899W WO2008051826A2 WO 2008051826 A2 WO2008051826 A2 WO 2008051826A2 US 2007081899 W US2007081899 W US 2007081899W WO 2008051826 A2 WO2008051826 A2 WO 2008051826A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
chosen
compound
independently chosen
salt
Prior art date
Application number
PCT/US2007/081899
Other languages
French (fr)
Other versions
WO2008051826A3 (en
Inventor
Irina Neagu
Andrew Roughton
Koc-Kan Ho
David Diller
Jui Hsiang Chan
Celia Kingsbury
Michael Ohlmeyer
Jacobus Cornelis Henricus Maria Wijkmans
Neeltje Miranda Teerhuis
Johannes Petrus Maria Lommerse
Original Assignee
N.V. Organon
Pharmacopeia Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2009533556A priority Critical patent/JP2010507581A/en
Application filed by N.V. Organon, Pharmacopeia Inc. filed Critical N.V. Organon
Priority to CA002666940A priority patent/CA2666940A1/en
Priority to AU2007309167A priority patent/AU2007309167A1/en
Priority to IN2154CHN2009 priority patent/IN2009CN02154A/en
Priority to BRPI0717435-7A priority patent/BRPI0717435A2/en
Priority to MX2009004154A priority patent/MX2009004154A/en
Priority to EP07844441A priority patent/EP2078019A2/en
Priority to US12/445,862 priority patent/US20110046131A1/en
Priority to CN2007800418805A priority patent/CN101657453B/en
Publication of WO2008051826A2 publication Critical patent/WO2008051826A2/en
Publication of WO2008051826A3 publication Critical patent/WO2008051826A3/en
Priority to IL198080A priority patent/IL198080A0/en
Priority to NO20091597A priority patent/NO20091597L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a chemical genus of purines which are useful as PKC 6> inhibitors.
  • PKC protein kinase C
  • PKC ⁇ is expressed predominantly in lymphoid tissue and skeletal muscle. It has been shown that PKC ⁇ is essential for TCR-mediated T-cell activation but inessential during TCR-dependent thymocyte development. PKC ⁇ , but not other PKC iso forms, translocates to the site of cell contact between antigen-specific T-cells and APCs, where it localizes with the TCR in the central core of the T-cell activation. PKC6*, but not the «,£; or ⁇ isoenzymes, selectively activated a FasL promoter-reporter gene and upregulated the mRNA or cell surface expression of endogenous FasL.
  • PKC ⁇ and £ promoted T-cell survival by protecting the cells from Fas-induced apoptosis, and this protective effect was mediated by promoting p90Rsk- dependent phosphorylation of BAD.
  • PKC ⁇ appears to play a dual regulatory role in T-cell apoptosis.
  • PKC ⁇ inhibitors are useful for the treatment or prevention of disorders or diseases mediated by T lymphocytes, for example, autoimmune disease such as rheumatoid arthritis and lupus erythematosus, and inflammatory disease such as asthma and inflammatory bowel diseases.
  • PKC ⁇ is identified as a drug target for immunosuppression in transplantation and autoimmune diseases (Isakov et al. (2002) Annual Review of Immunology, 20, 761-794).
  • PCT Publication WO2004/043386 identifies PKC#as a target for treatment of transplant rejection and multiple sclerosis.
  • PKC ⁇ also plays a role in inflammatory bowel disease (The Journal of Pharmacology and Experimental Therapeutics (2005), 313 (3), 962-982), asthma (WO 2005062918), and lupus (Current Drug Targets: Inflammation & Allergy (2005), 4 (3), 295-298).
  • PKC ⁇ is highly expressed in gastrointestinal stromal tumors (Blay, P. et al. (2004) Clinical Cancer Research, 10, 12, Pt.1), it has been suggested that PKC6> is a molecular target for treatment of gastrointestinal cancer (Wiedmann, M. et al. (2005) Current Cancer Drug Targets 5(3), 171).
  • small molecule PKC-theta inhibitors can be useful for treatment of gastrointestinal cancer.
  • PKC ⁇ inhibitors are useful in treatment of T-cell mediated diseases including autoimmune disease such as rheumatoid arthritis and lupus erythematosus, and inflammatory diseases such as asthma and inflammatory bowel disease.
  • PKC ⁇ inhibitors are useful in treatment of gastrointestinal cancer and diabetes.
  • the invention relates to compounds of the formula I:
  • R 1 is chosen from C 1 -C 4 alkyl, carbocyclyl, substituted carbocyclyl and wherein
  • R 4 is chosen from cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein R 4 may be substituted, with a proviso that when R 4 is a heteroaryl, R 4 is not bonded via a heteroatom to the methylene carbon bearing the Z group; and
  • Z is chosen from -H and C 1 -C 4 alkyl;
  • R 2 is chosen from -(C 2 -C 7 alkyl)-NR 5 R 6 , -(C 0 -C 4 alkyl)-R 7 -R 8 , and
  • R 7 is cyclyl, with a proviso that when R 7 is a heterocyclyl, a purine nitrogen of Formula I bonded to R 2 is not bonded to a heteroatom of R 7 directly or via a methylene group;
  • R 8 is chosen from -(C 0 -C 4 alkyl)-NR 5 R 6 , and
  • R 8 may additionally be -H, with a proviso that when R 7 is a heterocyclyl and R 8 is
  • R 5 R 6 a heteroatom of R 7 is not bonded to -NR 5 R 6 directly or via a methylene group;
  • R 5 and R 6 are independently chosen from -H and C 1 -C 4 alkyl;
  • R is chosen from C 1 -C 6 alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl and substituted heteroaryl; with a proviso that when R 3 is phenyl and R 2 is piperidin-4-yl-ethyl, R 1 is not cyclopropyl.
  • compositions comprising a pharmaceutically acceptable carrier and a compound of formula I, or salt thereof.
  • the invention in another aspect relates to a method for treating T-cell mediated diseases including autoimmune disease such as rheumatoid arthritis and lupus erythematosus, inflammatory diseases such as asthma and inflammatory bowel disease, cancer such as gastrointestinal cancer, and diabetes.
  • the method comprises administering a therapeutically effective amount of a compound of formula I, or salt thereof.
  • R 1 is chosen from C 1 -C 4 alkyl, carbocyclyl, substituted carbocyclyl and wherein
  • R 4 is chosen from cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein R 4 may be substituted, with a proviso that when R 4 is a heteroaryl, R 4 is not bonded via a heteroatom to the methylene carbon bearing the Z group; and Z is chosen from -H and C 1 -C 4 alkyl;
  • R 2 is chosen from -(C 2 -C 7 alkyl)-NR 5 R 6 , -(C 0 -C 4 alkyl)-R 7 -R 8 , and -(C 0 -C 4 alkyl)-C(0)-(Co-C 4 alkyl)-R 7 -R 8 , wherein R 7 is cyclyl, with a proviso that when R 7 is a heterocyclyl, a purine nitrogen of Formula I bonded to R 2 is not bonded to a heteroatom of R 7 directly or via a methylene group; R 8 is chosen from -(C 0 -C 4 alkyl)-NR 5 R 6 , and
  • R 8 may additionally be -H, with a proviso that when R 7 is a heterocyclyl and R 8 is -(C 0 -C 4 alkyl)— NR 5 R 6 , a heteroatom of R 7 is not bonded to -NR 5 R 6 directly or via a methylene group;
  • R 5 and R 6 are independently chosen from -H and C 1 -C 4 alkyl; and R is chosen from C 1 -C 6 alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl and substituted heteroaryl; with a proviso that when R 3 is phenyl and R 2 is piperidin-4-yl-ethyl, R 1 is not cyclopropyl.
  • R 1 is chosen from C 1 -C 4 alkyl, phenyl optionally substituted with one or two substituents independently chosen from halogen, OCH 3 , -CF 3 , -OCF 3 and C 1 -C 4
  • R 4 is -(C 0 -C 4 alkyl)-R 9 , wherein
  • R 9 is chosen from cycloalkyl, aryl, and heteroaryl, wherein R 9 is optionally substituted at one or two atoms with substituents independently chosen from halogen, -OH, -OCH 3 , -CF 3 , -OCF 3 , - CN, C 1 -C 4 alkyl, and pyridinyl; and Z is chosen from -H and C 1 -C 4 alkyl.
  • R 2 is chosen from -(C 2 -C 7 alkyl)-NR 5 R 6 , -(C 0 -C 4 alkyl)-R 7 -R 8 , and -(C 0 -C 4 alkyl)-C(O)-(C 0 -C 4 alkyl)-R 7 -R 8 ,
  • R 7 is chosen from alicyclyl, nitrogenous alicyclyl, aryl, and nitrogenous heteroaryl;
  • R 8 is chosen from -H, -(C 0 -C 4 alkyl)-NR 5 R 6 , and
  • R 5 and R 6 are independently chosen from -H and -(C 1 -C 4 alkyl).
  • R 3 is chosen from C 1 -C 6 alkyl, aryl, aryl substituted with R 10 , R 11 and R 12 ,
  • R 10 , R 11 and R 12 are independently chosen from -H, halogen, -OCH 3 ,
  • R 13 and R 14 are independently chosen from -H and C 1 -C 4 alkyl
  • R 22 , R 23 and R 24 are one or two substituents independently chosen from -H, C 1 -C 4 alkyl, C 1 -C 6 cycloalkyl, aryl, -(CH 2 ) n NR 26 R 27 and -(CH 2 ) n OR 28 said C 1 -C 4 alkyl and C 1 -C 6 cycloalkyl being optionally substituted with one or more halogens;
  • R 25 is C 1 -C 4 alkyl;
  • R 26 and R 27 are independently chosen from H and C 1 -C 4 alkyl or R 26 and R 27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O;
  • R 28 is chosen from H and C 1 -C 4 alkyl;
  • m is 0 , 1 or 2 and
  • n is 1, 2 or 3.
  • R 1 is chosen from C 1 -C 4 alkyl, phenyl optionally substituted with one or two substituents independently chosen from halogen, OCH3, -CF3, -OCF3 and C 1 -C 4
  • R 4 is chosen from
  • R 15 and R 16 are independently chosen from -H, halogen, -OH, -OCH 3 ,
  • R 17 is chosen from O and S;
  • R 18 is chosen from CH and N;
  • R 19 and R 20 are independently chosen from -H, halogen,
  • R 2 is chosen from -(C 2 -C 7 alkyl)-NR 5 R 6 ,
  • R 7 is chosen from cyclohexyl, phenyl, piperidinyl, pyrrolidinyl, morpholinyl, and piperazinyl;
  • R 8 is chosen from -H, -(C 0 -C 4 alkyl)-NR 5 R 6 , and
  • R 5 and R 6 are independently chosen from -H and -(C 1 -C 4 alkyl).
  • R is other than
  • R 3 is chosen from C 1 -C 6 alkyl, .
  • R 10 , R 11 and R 12 are independently chosen from -H, halogen, -OCH 3 ,
  • R 13 and R 14 are independently chosen from -H and C 1 -C 4 alkyl
  • R 22 , R 23 and R 24 are one or two substituents independently chosen from -H, C 1 -C 4 alkyl, C 1 -C 6 cycloalkyl, aryl, -(CH 2 ) n NR 26 R 27 and -(CH 2 ) n OR 28 said C 1 -C 4 alkyl and C 1 -C 6 cycloalkyl being optionally substituted with one or more halogens;
  • R 25 is C 1 -C 4 alkyl;
  • R 26 and R 27 are independently chosen from H and C 1 -C 4 alkyl or R 26 and R 27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O;
  • R 28 is chosen from H and C 1 -C 4 alkyl;
  • m is 0 , 1 or 2 and
  • n is 1, 2 or 3.
  • R is chosen from pyridyl, thienyl, thiazolyl and furanyl optionally substituted with methyl or halogen.
  • the invention relates to compounds of the formula I, or salt thereof:
  • R 1 is chosen from straight or branched C 1 -C 4 alkyl, phenyl optionally substituted with one or two substituents independently chosen from halogen, OCH 3 , -CF 3 ,
  • R 4 is -(C 0 -C 4 alkyl)-R 9 , wherein R 9 is chosen from cycloalkyl, aryl, and heteroaryl, wherein R 9 is optionally substituted at one or two atoms with substituents independently chosen from halogen, -OH, -OCH 3 , - CF 3 , -OCF 3 , -CN, C 1 -C 4 alkyl, and pyridinyl, with a proviso that when R 9 is a heteroaryl, R 9 is not bonded via a heteroatom to the methylene carbon bearing the Z group; and Z is chosen from -H and C 1 -C 4 alkyl;
  • R 2 is chosen from -(C 2 -C 7 alkyl)-NR 5 R 6 , -(C 0 -C 4 alkyl)-R 7 -R 8 , and -(C 0 -C 4 alkyl)-C(0)-(Co-C 4 alkyl)-R 7 -R 8 , wherein
  • R 7 is chosen from alicyclyl, nitrogenous alicyclyl, aryl, and nitrogenous heteroaryl, with a proviso that when R 7 is a nitrogenous alicyclyl or a nitrogenous heteroaryl, a purine nitrogen of Formula I bonded to R 2 is not bonded directly or via a methylene group to a nitrogen of R 7 ;
  • R 8 is chosen from, -(C 0 -C 4 alkyl)-NR 5 R 6 , and
  • R 8 may additionally be
  • R 7 is a nitrogenous alicyclyl or a nitrogenous heteroaryl and R 8 is -(C 0 -C 4 alkyl)— NR 5 R 6 , a nitrogen of R 7 is not bonded directly or via a methylene group to -NR 5 R 6 ;
  • R 5 and R 6 are independently chosen from -H and -(C 1 -C 4 alkyl); R 3 is chosen from C 1 -C 6 alkyl, aryl, aryl substituted with R 10 , R 11 and R 12 , wherein
  • R 10 , R 11 and R 12 are independently chosen from -H, halogen, -OCH 3 , -CF 3 , -OCF 3 , -CN, C 1 -C 4 alkyl, -NR 13 R 14 , -S(O) 1n CH 3 , -CONHR 22 , -NHCOR 23 , - OR 24 and -NHS(O) 1n R 25 ; wherein R 13 and R 14 are independently chosen from -H and C 1 -C 4 alkyl; R 22 , R 23 and R 24 are one or two substituents independently chosen from -H, C 1 -C 4 alkyl, C 1 -C 6 cycloalkyl, aryl, -(CH 2 ) n NR 26 R 27 and -(CH 2 ) n OR 28 said C 1 -C 4 alkyl and C 1 -C 6 cycloalkyl being optionally substituted with one or more halogens;
  • R 25 is C 1 -C 4 alkyl
  • R 26 and R 27 are independently chosen from H and C 1 -C 4 alkyl or
  • R 26 and R 27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O;
  • R 28 is chosen from H and C 1 -C 4 alkyl; m is 0 , 1 or 2 and n is 1 , 2 or 3
  • R 1 is chosen from C 1 -C 4 alkyl, phenyl optionally substituted with one or two substituents independently chosen from halogen, OCH 3 , -CF 3 , -OCF 3 and C 1 -C 4
  • R 15 and R 16 are independently chosen from -H, halogen, -OH, -OCH 3 ,
  • R 17 is chosen from O and S;
  • R 18 is chosen from CH and N; R 19 and R 20 are independently chosen from -H, halogen, -OCH 3 , -CF 3 , -OCF 3 , -CN, C 1 -C 4 alkyl, and pyridinyl; and Z is chosen from -H and C 1 -C 4 alkyl.
  • R 2 is chosen from -(C 2 -C 7 alkyl)-NR 5 R 6 ,
  • R 7 is chosen from cyclohexyl, phenyl, piperidinyl, pyrrolidinyl, morpholinyl, and piperazinyl;
  • R 8 is chosen from -H, -(C 0 -C 4 alkyl)-NR 5 R 6 , and
  • R 5 and R 6 are independently chosen from -H and -(C 1 -C 4 alkyl).
  • R is other than and
  • R is chosen from C 1 -C 6 alkyl
  • R 10 , R 11 and R 12 are independently chosen from -H, halogen, -OCH 3 ,
  • R 13 and R 14 are independently chosen from -H and C 1 -C 4 alkyl;
  • R 22 , R 23 and R 24 are one or two substituents independently chosen from -H, C 1 -C 4 alkyl, C 1 -C 6 cycloalkyl, aryl, -(CH 2 ) n NR 26 R 27 and -(CH 2 ) n OR 28 said C 1 -C 4 alkyl and C 1 -C 6 cycloalkyl being optionally substituted with one or more halogens;
  • R 25 is C 1 -C 4 alkyl
  • R 26 and R 27 are independently chosen from H and C 1 -C 4 alkyl or
  • R 26 and R 27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O;
  • R 28 is chosen from H and C 1 -C 4 alkyl; m is 0 , 1 or 2 and n is 1, 2 or 3.
  • R 3 is chosen from pyridyl, thienyl, thiazolyl and furanyl optionally substituted with methyl or halogen
  • R 1 is R 4
  • R 4 is chosen from and
  • R 15 and R 16 are independently chosen from -H, halogen, -OH, -OCH 3 ,
  • R 17 is chosen from O and S; R 18 is chosen from CH and N; R 19 and R 20 are independently chosen from -H, halogen, -OCH 3 , -CF 3 , -OCF 3 , -CN, C 1 -C 4 alkyl, and pyridinyl; and is chosen from -H and C 1 -C 4 alkyl.
  • R 2 is chosen from
  • R is chosen from
  • R 3 is wherein
  • R 10 , R 11 and R 12 are independently chosen from -H, halogen, -OCH 3 ,
  • R 13 and R 14 are independently chosen from -H and C 1 -C 4 alkyl
  • R 22 , R 23 and R 24 are one or two substituents independently chosen from -H, C 1 -C 4 alkyl, C 1 -C 6 cycloalkyl, aryl, -(CH 2 ) n NR 26 R 27 and
  • R 25 is C 1 -C 4 alkyl
  • R 26 and R 27 are independently chosen from H and C 1 -C 4 alkyl or
  • R 26 and R 27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O;
  • R 28 is chosen from H and C 1 -C 4 alkyl; m is 0 , 1 or 2 and n is 1, 2 or 3.
  • R is chosen from pyridyl, thienyl, thiazolyl and furanyl optionally substituted with methyl or halogen.
  • the invention relates to compounds of the formula I, or salt thereof:
  • R 1 is chosen from C 1 -C 4 alkyl, phenyl optionally substituted with one or two substituents independently chosen from halogen, OCH 3 , -CF 3 , -OCF 3 and C 1 -C 4 alkyl,
  • R 4 is chosen from wherein
  • R 15 and R 16 are independently chosen from -H, halogen, -OH, -OCH 3 , - CF 3 , -OCF 3 , -CN, C 1 -C 4 alkyl, and pyridinyl;
  • R 17 is chosen from O and S;
  • R , 1 l 8 ⁇ is chosen from CH and N;
  • R 19 and R 20 are independently chosen from -H, halogen,
  • Z is chosen from -H and C 1 -C 4 alkyl;
  • R 2 is chosen from -(C 2 -C 7 alkyl)-NR 5 R 6 , -(C 0 -C 4 alkyl)-R 7 -R 8 , and
  • R 7 is chosen from cyclohexyl, phenyl, piperidinyl, pyrrolidinyl, morpholinyl, and piperazinyl;
  • R 8 is chosen from -H, -(C 0 -C 4 alkyl)-NR 5 R 6 , and
  • R 5 and R 6 are independently chosen from -H and -(C 1 -C 4 alkyl); and R 2 contains a basic N atom located from 2 to 8 atoms distant from its point of attachment to the purine ring;
  • R 3 is chosen from C 1 -C 6 alkyl, and wherein
  • R 10 , R 11 and R 12 are independently chosen from -H, halogen, -OCH 3 ,
  • R 13 and R 14 are independently chosen from -H and C 1 -C 4 alkyl
  • R 22 , R 23 and R 24 are one or two substituents independently chosen from -H, C 1 -C 4 alkyl, C 1 -C 6 cycloalkyl, aryl, -(CH 2 ) n NR 26 R 27 and
  • R 25 is C 1 -C 4 alkyl
  • R 26 and R 27 are independently chosen from H and C 1 -C 4 alkyl or
  • R 26 and R 27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O;
  • R 28 is chosen from H and C 1 -C 4 alkyl; m is O , 1 or 2 and n is 1 , 2 or 3 [0034] In another embodiment R 3 is chosen from pyridyl, thienyl, thiazolyl and furanyl optionally substituted with methyl or halogen.
  • N atoms When reference is made to a basic N atom, such N atom has a lone pair of electrons available for protonation. N atoms with a basicity below pKb of about 9 are preferred. More preferred are N atoms which exhibit pKb below 7. Such basic N atom may be primary, secondary, or tertiary amine, in linear, branched or cyclic system. Examples of R 2 containing basic N atom located from 2 to 8 atoms distant from its point of attachment to the purine ring are:
  • R 1 is R '
  • R is chosen from and
  • R 15 and R 16 are independently chosen from -H, halogen, -OH, -OCH 3 ,
  • R 17 is chosen from O and S;
  • R 18 is chosen from CH and N;
  • R 19 and R 20 are independently chosen from -H, halogen, -OCH 3 ,
  • R 2 is not
  • R is chosen from
  • R is chosen from
  • R 3 is
  • R 10 , R 11 and R 12 are independently chosen from -H, halogen, -OCH 3 , -CF 3 , -OCF 3 , -CN, C 1 -C 4 alkyl, -NR 13 R 14 , -S(O) 1n CH 3 , -CONHR 22 , -NHCOR 23 , OR 24 and -NHS(O) 1n R 25 ; wherein
  • R 13 and R 14 are independently chosen from -H and C 1 -C 4 alkyl;
  • R 22 , R 23 and R 24 are one or two substituents independently chosen from -H, C 1 -C 4 alkyl, C 1 -C 6 cycloalkyl, aryl, -(CH 2 ) n NR 26 R 27 and -(CH 2 ) n OR 28 said C 1 -C 4 alkyl and C 1 -C 6 cycloalkyl being optionally substituted with one or more halogens;
  • R 25 is C 1 -C 4 alkyl;
  • R 26 and R 27 are independently chosen from H and C 1 -C 4 alkyl or R 26 and R 27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O;
  • R 28 is chosen from H and C 1 -C 4 alkyl;
  • m is 0 , 1 or 2 and
  • n is 1, 2 or 3.
  • R is chosen from pyridyl, thienyl, thiazolyl and furanyl optionally substituted with methyl or halogens.
  • the invention is directed to a method of treatment of a T-cell mediated disease comprising administering a therapeutically effective amount of a compound of formula I, or salt thereof.
  • the T-cell mediated disease may be, for example, an autoimmune disease or an inflammatory disease.
  • the autoimmune disease may be, for example, rheumatoid arthritis or lupus erythematosus.
  • the inflammatory disease may be, for example, asthma or inflammatory bowel disease.
  • the invention is directed to a method of treatment of cancer, such as gastrointestinal cancer, comprising administering a therapeutically effective amount of a compound of formula I, or salt thereof.
  • the invention is directed to a method of treatment of diabetes comprising administering a therapeutically effective amount of a compound of formula I, or salt thereof.
  • Alkyl and alkane are intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof.
  • Lower alkyl refers to alkyl groups of from 1 to 6 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s-and t-butyl and the like. Preferred alkyl groups are those Of C 2 O or below.
  • Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of from 3 to 8 carbon atoms. Examples of cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbornyl and the like.
  • (C 1 to C n ) Hydrocarbon includes alkyl, cycloalkyl, alkenyl, alkynyl, aryl and combinations thereof containing only hydrogen and one to n carbons. Examples include vinyl, allyl, cyclopropyl, propargyl, phenethyl, cyclohexylmethyl, camphoryl and naphthylethyl. Saturated (C 1 to C n )hydrocarbon is identical in meaning to (C 1 to C n )alkyl or (C 1 to C n )alkane as used herein. Whenever reference is made to C 0 - n alkyl, (C 0 to C n )alkyl, or (C 0 to C n )alkane when number of carbon atoms is 0, a direct bond is implied.
  • Alkoxy or alkoxyl refers to groups of from 1 to 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof attached to the parent structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to four carbons.
  • Fluoroalkyl refers to alkyl residues in which one or more hydrogens have been replaced by fluorine. It includes perfluoroalkyl, in which all the hydrogens have been replaced by fluorine. Examples include fluoromethyl, difluoromethyl, trifluoromethyl, trifluoroethyl and pentafluoroethyl.
  • Oxaalkyl refers to alkyl residues in which one or more carbons (and their associated hydrogens) have been replaced by oxygen. Examples include methoxypropoxy, 3,6,9- trioxadecyl and the like.
  • the term oxaalkyl is intended as it is understood in the art [see Naming and Indexing of Chemical Substances for Chemical Abstracts, published by the American Chemical Society, 1(196, but without the restriction of ]
  • thiaalkyl and azaalkyl refer to alkyl residues in which one or more carbons has been replaced by sulfur or nitrogen, respectively. Examples include ethylaminoethyl and methylthiopropyl.
  • Acyl refers to groups of from 1 to 8 carbon atoms of a straight, branched, cyclic configuration, saturated, unsaturated and aromatic and combinations thereof, attached to the parent structure through a carbonyl functionality.
  • One or more carbons in the acyl residue may be replaced by nitrogen, oxygen or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples include acetyl, benzoyl, propionyl, isobutyryl, t-butoxycarbonyl, benzyloxycarbonyl and the like.
  • Lower-acyl refers to groups containing one to four carbons.
  • Cyclyl refers to a 3- to 8-membered ring containing 0-3 heteroatoms selected from O, N, or S; a bicyclic 9- or 10-membered ring system containing 0-3 heteroatoms selected from O, N, or S; or a tricyclic 13- or 15-membered ring system containing 0-3 heteroatoms selected from O, N, or S. Cyclyl may be saturated, unsaturated, or aromatic.
  • a carbocyclyl is a cyclyl lacking any heteroatoms. As commonly understood, when referring to cyclyl as a substituent, it is intended that the point of attachment is a ring carbon or heteroatom of the cyclyl group.
  • Cyclylalkyl refers to an alkyl residue attached to a cyclyl. As commonly understood, when referring to cyclylalkyl as a substituent, it is intended that the point of attachment is the alkyl group.
  • Cycloalkylalkyl refers to an alkyl residue attached to a cycloalkyl. As commonly understood, when referring to cycloalkylalkyl as a substituent, it is intended that the point of attachment is the alkyl group.
  • Alicyclyl refers to aliphatic compounds having a carbocyclic ring structure which may be saturated or unsaturated, but may not be a benzenoid or other aromatic system.
  • Alicyclyl may be a 3- to 8-membered ring containing 0-3 heteroatoms selected from O, N, or S; a bicyclic 9- or 10-membered ring system containing 0-3 heteroatoms selected from O, N, or S; or a tricyclic 13- or 15-membered ring system containing 0-3 heteroatoms selected from O, N, or S.
  • a carboalicyclyl is an alicyclyl lacking any heteroatoms. As commonly understood, when referring to alicyclyl as a substituent, it is intended that the point of attachment is a ring carbon or heteroatom of the alicyclyl group.
  • Alicyclylalkyl refers to an alkyl residue attached to an alicyclyl. As commonly understood, when referring to alicyclylalkyl as a substituent, it is intended that the point of attachment is the alkyl group.
  • Aryl and heteroaryl mean a 5- or 6-membered aromatic or heteroaromatic ring containing 0-3 heteroatoms selected from O, N, or S; a bicyclic 9- or 10-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, or S; or a tricyclic 13- or 14-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, or S.
  • aryl when referring to aryl as a substituent, it is intended that the point of attachment is a ring carbon of the aryl group (or ring carbon or heteroatom of the heteroaryl).
  • aryl and heteroaryl refer to systems in which at least one ring, but not necessarily all rings, are fully aromatic.
  • aromatic 6- to 14- membered carbocyclic rings include, e.g., benzene, naphthalene, indane, tetralin, benzocycloheptane and fluorene and the 5- to 10-membered aromatic heterocyclic rings include, e.g., imidazole, pyridine, indole, isoindoline, thiophene, benzopyranone, thiazole, furan, benzimidazole, quinoline, isoquinoline, tetrahydroisoquinoline, quinoxaline, tetrahydrocarboline, pyrimidine, pyrazine, tetrazole and pyrazole.
  • Arylalkyl means an alkyl residue attached to an aryl ring. As commonly understood, when referring to arylalkyl as a substituent, it is intended that the point of attachment is the alkyl group. Examples of arylalkyl are benzyl, phenethyl, phenylpropyl and naphthylethyl. Heteroarylalkyl means an alkyl residue attached to a heteroaryl ring. Examples include, e.g., pyridinylmethyl, pyrimidinylethyl and the like.
  • Heterocycle means a cycloalkyl or aryl residue in which from one to three carbons is replaced by a heteroatom selected from the group consisting of N, O and S.
  • the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
  • Heterocycles also include spiroheterocycles. It is to be noted that heteroaryl is a subset of heterocycle in which the heterocycle is aromatic.
  • heterocyclyl residues additionally include piperazinyl, 4-piperidinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinylsulfoxide, thiamorpholinylsulfone, oxadiazolyl, triazolyl and tetrahydroquinolinyl.
  • cyclyl Whenever reference is made to nitrogen attached cyclyl or nitrogenous cyclyl (where cyclyl may be identified as heterocyclyl, alicyclyl, or heteroaryl) such cyclyl contains at least one N atom, but may also contain additional 0-3 heteroatoms selected from O, N, or S.
  • Aminoalkyl means an amino group bound to a core structure via an alkyl group, e.g., aminomethyl, aminoethyl, aminopenthyl, etc.
  • alkyl group could be straight or branched and, therefore, an aminoalkyl includes, e.g., -CH 2 CH 2 CH(CH S )CH 2 NH 2 , - CH 2 C(CHs) 2 CH 2 NH 2 , etc.
  • Alkylaminoalkyl means a secondary amine bound to a core structure via an alkyl group, e.g., -CH 2 CH 2 NHCH 3 , -CH2CH2CH 2 NHCH 2 CH 3 , etc.
  • Dialkylaminoalkyl means a tertiary amine bound to a core structure via an alkyl group, e.g., -CH 2 N(CH 3 ) 2 ,
  • Substituted alkyl, cyclyl, aryl, cycloalkyl, heterocyclyl etc. refer to alkyl, cyclyl, aryl, cycloalkyl, or heterocyclyl wherein up to three H atoms in each residue are replaced with loweralkyl, halogen, haloalkyl, hydroxy, hydroxymethyl, loweralkoxy, perfluoroloweralkoxy, carboxy, carboalkoxy (also referred to as alkoxycarbonyl), carboxamido (also referred to as alkylaminocarbonyl), sulfonamido, aminosulfonyl, alkylaminosulfonyl, cyano, carbonyl, nitro, amino, alkylamino, dialkylamino, ureido, alkylureido, mercapto, alkylthio, sulfoxide, sulfone, acylamino, amidino
  • halogen means fluorine, chlorine, bromine or iodine.
  • treatment or “treating” a patient are intended to include prophylaxis.
  • the terms include amelioration, prevention and relief from the symptoms and/or effects associated with these disorders.
  • the terms “preventing” or “prevention” refer to administering a medicament beforehand to forestall or obtund an attack. Persons of ordinary skill in the medical art (to which the present method claims are directed) recognize that the term “prevent” is not an absolute term. In the medical art it is understood to refer to the prophylactic administration of a drug to diminish the likelihood or seriousness of a condition, and this is the sense intended.
  • Boc t-butyloxy carbonyl
  • CDI carbonyl diimidazole
  • DIEA N,N-diisopropylethyl amine
  • EEDQ 2-ethoxy- 1 -ethoxycarbonyl- 1 ,2-dihydroquinoline
  • FCC flash column chromography
  • HATU O-(7- Azabenzotriazol- 1 -yl)- 1 , 1 ,3 ,3 -tetramethyluronium hexafluorophosphate
  • HOBt hydroxybenzotriazole
  • the compounds of the present invention may be prepared by the methods illustrated in the general reaction schemes as, for example, described below, or by modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants that are in themselves known, but are not mentioned here.
  • Displacement of the two chlorides in 2,4-dichloro-5-nitropyrimidine 1 usually occurs in a regioselective manner.
  • the more reactive chloride in the 2-position is first displaced by an amine R 5 NH 2 to yield compound 2.
  • Addition of a second amine R"NH 2 displaces the chloride in the 4-position.
  • Reduction of the nitro group in 3 to an amine using reagents well known in the art e.g. Raney Ni/ H 2 , Fe/EtOH/aqAcOH, Na 2 S 2 ⁇ 4 /NH 4 OH/H 2 ⁇ /Dioxane
  • reagents well known in the art e.g. Raney Ni/ H 2 , Fe/EtOH/aqAcOH, Na 2 S 2 ⁇ 4 /NH 4 OH/H 2 ⁇ /Dioxane
  • the purine analogs of the invention may be prepared on solid support (Scheme 2).
  • an acid cleavable linker can be attached to the Argogel-NH 2 resin.
  • the resin with the linker is first reductive aminated with a R 5 NH 2 .
  • the pyrimidine 2 which is similarly prepared from the first step in Scheme 1, is then attached to the amine by a nucleophilic displacement reaction. Reduction of the nitro group, followed by ring closure with an aldehyde, yields the purine.
  • the product can then be released from the solid support by treatment with acid such as trifloroacetic acid.
  • Step 1 Reductive animation with a primary amine
  • the shaking vessel was then drained, and the resin was washed with CH 3 OH (IX), CH 2 Cl 2 (2X), CH 3 OH (IX), CH 2 Cl 2 (2X), CH 3 OH (IX), CH 3 OH (1X30 min) and CH 2 Cl 2 (2X).
  • the resulting resin-bound secondary amine 17 gave a positive result with the bromophenol blue staining test.
  • the resin was dried in vacuo.
  • Step 2 N-arylation with a 4-amino-2-chloro-5-nitropyrimidine
  • the skaking vessel was drained and the resin was washed with DMF (2X), CH 2 Cl 2 (IX), DMF (IX), CH 2 Cl 2 (2X), CH 3 OH (2X) and CH 2 Cl 2 (2X).
  • the resulting resin-bound nitropyrimidine resin 18 gave a negative result with the bromophenol blue staining tests.
  • the resin was dried in vacuo.
  • Step 3 Reduction of the nitro group
  • the shaking vessel was recharged with 60 mL of a freshly prepared 0.5 M solution of sodium hydrosulfite in 40 mL of water and 20 mL of dioxane and 0.93 mL of a saturated aqueous solution of ammonia that was prepared as described above.
  • the suspension was shaken at 25 °C for 16 h.
  • the shaking vessel was drained and the resin was washed with water: 1,4-dioxane 2:1 (v/v) (2X), anhydrous CH 3 OH (2X), anhydrous DMF (2X), CH 2 Cl 2 (2X) and anhydrous THF (2X).
  • the resulting resin-bound 5-aminopyrimidine 19 gave a positive result with the bromophenol blue staining test.
  • the resin was dried in vacuo.
  • the vial was recharged with 2.0 mL of a solution of 10.8 mmol (0.9 M, 12.5 equiv.) of the same aldehyde in 10.8 mL of JV,iV-dimethylacetamide and 0.2 mL of acetic acid.
  • the resin suspension was heated at 100 °C for 16 h, then allowed to cool to 25 °C and transferred to a small shaking vessel. The vessel was drained and the resin was washed with DMF (4X), CH 2 Cl 2 (2X), CH 3 OH (2X) and CH 2 Cl 2 (2X). The resulting resin-bound purine 20 was dried in vacuo.
  • the TFA salt was converted into the HCl salt by adding portions of 20 mL of a 1 M solution of HCl in ethanol (Alfa Aesar), stirring for 15 min at room temperature and in vacuo removing the solvent. The procedure was repeated 5 times. The sample was triturated with ether to give a light yellow solid, that recrystallized from methylene chloride / hexanes as a white solid (105 mg after being dried for 16 h over P 2 O 5 under high vacuum at 40 °C).
  • R 3 is an ortho- monochloroaryl with an amide at the /? ⁇ ra-position is described in the scheme below (Scheme 13.).
  • Commercially available acid 42 can be first reduced and subsequently reoxidized to aldehyde 44. After ringclosing reaction to the substituted purines, the bromide can be transformed to the acid which can be functionalized to e.g. an amide by procedures well known in the art (e.g. R-NH 2 /TBTU/DIEA/DCM).
  • Oxalylchloride (6.9 g, 54 mmol, 1.3 equiv.) was dissolved in DCM (153 ml) and cooled to -78 °C. To the cooled solution was a solution of DMSO ( 4.72 ml, 66.5 mmol, 1.6 equiv.) in DCM (57 ml) added dropwise and stirred for 15 minutes at -78 °C. Compound 43 (9.2 g, 41.5 mmol, 1.0 equiv.) was dissolved in DCM (116ml) and added dropwise while the temperature was maintained at -78 °C. The r.m. was stirred for 2 h at -78 °C.
  • the nitrogroup of 55 can be reduced by procedures well known in the art (e.g. Raney Ni).
  • the primary amine can be functionalized to e.g. a reversed amide by procedures well known in the art (e.g. R-NH 2 /TBTU/DIEA/DCM).
  • the Cbz-N-group can be deprotected by procedures well known in the art (e.g. Pd/C/H2).
  • the primary amine can be functionalized to e.g. a carbamate or reversed amide by procedures well known in the art (e.g. R-NH 2 /TBTU/DIEA/DCM).
  • the activity of the compounds described in the present invention may be determined by the following procedure. This procedure describes a kinase assay that measures the phosphorylation of a fluorescently-labeled peptide by full-length human recombinant active PKC ⁇ via fluorescent polarization using commercially available IMAP reagents. [0095] The PKC ⁇ used is made from full-length, human cDNA (accession number
  • PKC ⁇ is expressed using the baculovirus expression system.
  • the protein is purified with Ni-NTA affinity chromatography yielding a protein with 91% purity.
  • the substrate for this assay is a fluorescently-labeled peptide having the sequence
  • LHQRRGSIKQAKVHHVK (FITC)-NH 2 .
  • the stock solution of the peptide is 2 mM in water.
  • the IMAP reagents come from the IMAP Assay Bulk Kit, product #R8063 or
  • the kit materials include a 5X IMAP Binding Buffer and the IMAP Binding Reagent.
  • the Binding Solution is prepared as a 1 :400 dilution of IMAP Binding Reagent into the IX IMAP Binding Buffer.
  • the substrate/ATP buffer for this assay consists of 20 mM HEPES, pH 7.4 with 5 mM MgCl 2 , and 0.01% Tween-20. Additionally, the buffer contains 100 nM substrate, 20 ⁇ M ATP, and 2 mM DTT which are added fresh just prior to use.
  • the kinase buffer containing the PKC ⁇ consists of 20 mM HEPES, pH 7.4 with 0.01% Tween-20. This buffer also contains .2 ng/ ⁇ L PKC ⁇ and 2 mM DTT which are added fresh just prior to use.
  • the plates used are Corning 3710 (Corning Incorporated, Corning, NY). These are non-treated black polystyrene, 384-well with flat-bottoms. The serial dilutions are performed Nunc V-bottom 96-well plates.
  • the assay procedure starts the preparation of stock solutions of compounds at 10 mM in 100% DMSO.
  • the stock solutions and the control compound are serially diluted 1 :3.16 a total of 11 times into DMSO (37 ⁇ L of compound into 80 ⁇ L of DMSO).
  • a further dilution is performed by taking 4 ⁇ L compound and adding to 196 ⁇ L substrate/ ATP Buffer.
  • 10 ⁇ L aliquots of the compounds are transferred to the Costar 3710 plate.
  • the kinase reaction is initiated by the addition of 10 ⁇ L PKC ⁇ . This reaction is allowed to incubate for 1 hour at ambient temperature.
  • the reaction is then quenched by the addition of 60 ⁇ L of Binding Solution.
  • the plate is incubated for an additional 30 minutes at ambient temperature.
  • the assay is measured using an AcquestTM Ultra-HTS Assay Detection System (Molecular Devices) in fluorescence polarization mode using 485 nm excitation and 530 nm emission.
  • the activity of the compounds of the present invention is determined by the following procedure. This procedure describes a kinase assay that measures the phosphorylation of a fluorescently-labeled peptide by full-length human recombinant active PKC ⁇ via fluorescent polarization using commercially available IMAP reagents.
  • the PKC ⁇ used is made from full-length, human cDNA (accession number
  • PKC ⁇ is expressed using the baculovirus expression system.
  • the protein is purified with Ni-NTA affinity chromatography yielding a protein with -70% purity.
  • the substrate for this assay is a fluorescently-labeled peptide having the sequence
  • LHQRRGSIKQAKVHHVK (FITC)-NH 2 .
  • the stock solution of the peptide is 0.06M in MiIIiQ water.
  • the IMAP reagents originate from the IMAP buffer kit with Progressive Binding
  • the Binding Solution is prepared as a 1 :400 dilution of IMAP Progressive Binding Reagent into the IX buffer A IMAP Binding Buffer.
  • the kinase reaction buffer for this assay consists of 10 mM Tris-HCl, 10 mM
  • the plates used are Black 384-F Optiplates (product # 6007279, Packard).
  • the assay procedure starts with the preparation of serial dilutions of the compounds stored in 100% DMSO.
  • the compounds are 10 times serially diluted 1 :3.16, resulting in a final compound concentration range from 10 ⁇ M to 0.316 nM.. All reagent solutions are prepared in kinase reaction buffer.
  • Table 1 illustrates several examples of the compounds of the invention. These compounds are synthesized using one of the suitable procedures described above. The molecular weight of the compounds is confirmed by mass spectroscopy (m/z). The compounds of Table 1 are tested using one of the above-described PKC ⁇ IMAP assays. Entries in the 100, 200 , 300 and 400 series are tested using PKC-theta IMAP assay 1 and Entries in the 500, 600 and 700 are tested using PKC-theta IMAP assay II.
  • Page l45 of 173 cell mediated diseases including autoimmune disease such as rheumatoid arthritis and lupus erythematosus, and inflammatory diseases such as asthma and inflammatory bowel disease. Additionaly, the compounds of the invention are useful in treatment of gastrointestinal cancer and diabetes.
  • Table 2 also shows selectivity of the compounds of the invention by showing their IC50 values for SGK kinase. Entries identified with “1” had values above 250 nM; entries identified with “2” had values above 1 ⁇ M; entries identified with "3” had values above 10 ⁇ M.
  • IL-2 is a T cell-derived lymphokine that modulates immunological effects on many cells of the immune system, including cytotoxic T cells, natural killer cells, activated B cells and lymphokine-activated cells. It is a potent T cell mitogen that is required for the T cell proliferation, promoting their progression from Gl to S phase of the cell cycle. It is a growth factor for all subpopulations of T lymphocytes, as well as stimulating the growth of NK cells. It also acts as a growth factor to B cells and stimulates antibody synthesis. [00115] Due to its effects on both T and B cells, IL-2 is a major central regulator of immune responses. It plays a role in anti-inflammatory reactions, tumor surveillance, and hematopoiesis.
  • IL-2 although useful in the immune response, also causes a variety of problems. IL-2 damages the blood-brain barrier and the endothelium of brain vessels. These effects may be the underlying causes of neuropsychiatric side effects observed under IL-2 therapy, e.g. fatigue, disorientation and depression. It also alters the electrophysiological behavior of neurons.
  • T cells that are unable to produce IL-2 become inactive (anergic). This renders them potentially inert to any antigenic stimulation they might receive in the future.
  • agents which inhibit IL-2 production may be used for immunosupression or to treat or prevent inflammation and immune disorders. This approach has been clinically validated with immunosuppressive drugs such as cyclosporin, FK506, and RS61443.
  • Tables 1-3 demonstrates utility of the compounds of the invention in inhibition of PKC ⁇ and their utility for treatment of T-cell mediated diseases including autoimmune diseases such as rheumatoid arthritis, lupus erythematosus, and multiple sclerosis, inflammatory diseases such as asthma and inflammatory bowel disease, transplant rejection, gastrointestinal cancer, and diabetes.
  • autoimmune diseases such as rheumatoid arthritis, lupus erythematosus, and multiple sclerosis
  • inflammatory diseases such as asthma and inflammatory bowel disease
  • transplant rejection transplant rejection
  • gastrointestinal cancer gastrointestinal cancer
  • Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisometric forms which may be defined in terms of absolute stereochemistry as (R)- or (S)-.
  • the present invention is meant to include all such possible diastereomers as well as their racemic and optically pure forms.
  • Optically active (R)- and (S)- isomers may be prepared using homo-chiral synthons or homo- chiral reagents, or optically resolved using conventional techniques.
  • the compounds described herein contain olefmic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended to include both (E)- and (Z)- geometric isomers.
  • the present invention includes compounds of formula (I) in the form of salts.
  • Suitable salts include those formed with both organic and inorganic acids. Such salts will normally be pharmaceutically acceptable, although non-pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question.
  • pharmaceutically acceptable salt refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids and bases and organic acids and bases. When the compounds of the present invention are basic, salts may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids.
  • Suitable pharmaceutically acceptable acid addition salts for the compounds of the present invention include acetic, benzenesulfonic (besylate), benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric acid, p-toluenesulfonic, and the like.
  • suitable pharmaceutically acceptable base addition salts for the compounds of the present invention include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.
  • metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc
  • organic salts made from lysine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically carriers thereof and optionally one or more other therapeutic ingredients.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), rectal and topical (including dermal, buccal, sublingual and intraocular) administration.
  • the most suitable route may depend upon the condition and disorder of the recipient.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof ("active ingredient”) with the carrier which constitutes one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated so as to provide sustained, delayed or controlled release of the active ingredient therein.
  • Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient.
  • Formulations for parenteral administration also include aqueous and non-aqueous sterile suspensions, which may include suspending agents and thickening agents.
  • the formulations may be presented in unit- dose of multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of a sterile liquid carrier, for example saline, phosphate-buffered saline (PBS) or the like, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • Formulations for rectal administration may be presented as a suppository with the usual carriers, such as cocoa butter or polyethylene glycol.
  • Formulations for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.
  • Preferred unit dosage formulations are those containing an effective dose, or an appropriate fraction thereof, of the active ingredient.
  • compositions will usually include a "pharmaceutically acceptable inert carrier” and this expression is intended to include one or more inert excipients, which include starches, polyols, granulating agents, microcrystalline cellulose, diluents, lubricants, binders, disintegrating agents, and the like. If desired, tablet dosages of the disclosed compositions may be coated by standard aqueous or nonaqueous techniques. “Pharmaceutically acceptable carrier” also encompasses controlled release means. Compositions of the present invention may also optionally include other therapeutic ingredients, anti-caking agents, preservatives, sweetening agents, colorants, flavors, desiccants, plasticizers, dyes, and the like.
  • the compounds of formula (I) are preferably administered orally or by injection (intravenous or subcutaneous).
  • the precise amount of compound administered to a patient will be the responsibility of the attendant physician. However, the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity. Also, the route of administration may vary depending on the condition and its severity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A chemical genus of purines, which are useful as PKCϑ inhibitors, is disclosed. The genus is represented by the formula (I); A representative example is: (II)

Description

PURINES AS PKC-THETA INHIBITORS
Field of the Invention
[0001] The present invention relates to a chemical genus of purines which are useful as PKC 6> inhibitors.
Background of the Invention
[0002] Members of the protein kinase C (PKC) family of serine/threonine kinases play critical roles in the regulation of cellular differentiation and proliferation of diverse cell types. Ten mammalian members of PKC family have been identified and designated a, β, γ, δ, ε, ζ, η, θ, μ, and λ. The structure of PKC θ displays the highest homology with members of the Ca2+ independent novel PKC subfamily, including PKCδ, ε, and η. PKC θ is most highly related to PKCδ.
[0003] PKC θ is expressed predominantly in lymphoid tissue and skeletal muscle. It has been shown that PKC θ is essential for TCR-mediated T-cell activation but inessential during TCR-dependent thymocyte development. PKC θ, but not other PKC iso forms, translocates to the site of cell contact between antigen-specific T-cells and APCs, where it localizes with the TCR in the central core of the T-cell activation. PKC6*, but not the«,£; or ^isoenzymes, selectively activated a FasL promoter-reporter gene and upregulated the mRNA or cell surface expression of endogenous FasL. On the other hand, PKC θ and £ promoted T-cell survival by protecting the cells from Fas-induced apoptosis, and this protective effect was mediated by promoting p90Rsk- dependent phosphorylation of BAD. Thus, PKC θ appears to play a dual regulatory role in T-cell apoptosis.
[0004] The selective expression of PKC θ in T-cells and its essential role in mature T- cell activation establish that PKC θ inhibitors are useful for the treatment or prevention of disorders or diseases mediated by T lymphocytes, for example, autoimmune disease such as rheumatoid arthritis and lupus erythematosus, and inflammatory disease such as asthma and inflammatory bowel diseases.
[0005] PKC θ is identified as a drug target for immunosuppression in transplantation and autoimmune diseases (Isakov et al. (2002) Annual Review of Immunology, 20, 761-794). PCT Publication WO2004/043386 identifies PKC#as a target for treatment of transplant rejection and multiple sclerosis. PKC θ also plays a role in inflammatory bowel disease (The Journal of Pharmacology and Experimental Therapeutics (2005), 313 (3), 962-982), asthma (WO 2005062918), and lupus (Current Drug Targets: Inflammation & Allergy (2005), 4 (3), 295-298).
[0006] In addition, PKC θ is highly expressed in gastrointestinal stromal tumors (Blay, P. et al. (2004) Clinical Cancer Research, 10, 12, Pt.1), it has been suggested that PKC6> is a molecular target for treatment of gastrointestinal cancer (Wiedmann, M. et al. (2005) Current Cancer Drug Targets 5(3), 171). Thus, small molecule PKC-theta inhibitors can be useful for treatment of gastrointestinal cancer.
[0007] Experiments conduced in PKC θ knock-out mice led to the conclusion that PKC θ inactivation prevented fat-induced defects in insulin signalling and glucose transport in skeletal muscle (Kim J. et al, 2004, The J. of Clinical Investigation 114 (6), 823). This data suggests that PKC θ is a potential therapeutic target for the treatment of type 2 diabetes, and hence small molecule PKC θ inhibitors can be useful for treating such disease.
[0008] Therefore, PKC θ inhibitors are useful in treatment of T-cell mediated diseases including autoimmune disease such as rheumatoid arthritis and lupus erythematosus, and inflammatory diseases such as asthma and inflammatory bowel disease. In addition, PKC θ inhibitors are useful in treatment of gastrointestinal cancer and diabetes.
[0009] Japanese application number 2003-008019, published on August 5, 2004 under publication number JP 2004-217582, discloses purine derivatives having alleged utility as TNA- alpha production inhibitors and PDE4 inhibitors. Summary of the Invention
[0010] In one aspect, the invention relates to compounds of the formula I:
wherein:
Figure imgf000004_0001
R1 is chosen from C1 -C4 alkyl, carbocyclyl, substituted carbocyclyl and
Figure imgf000004_0002
wherein
R4 is chosen from cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein R4 may be substituted, with a proviso that when R4 is a heteroaryl, R4 is not bonded via a heteroatom to the methylene carbon bearing the Z group; and
Z is chosen from -H and C1-C4 alkyl; R2 is chosen from -(C2-C7 alkyl)-NR5R6, -(C0-C4 alkyl)-R7-R8, and
-(C0-C4 alkyl)-C(O)-(C0-C4 alkyl)-R7-R8, wherein
R7 is cyclyl, with a proviso that when R7 is a heterocyclyl, a purine nitrogen of Formula I bonded to R2 is not bonded to a heteroatom of R7 directly or via a methylene group;
R8 is chosen from -(C0-C4 alkyl)-NR5R6, and
-C(O)-(C0-C4 alkyl)-NR5R6, and, when R7 is nitrogenous heterocyclyl,
R8 may additionally be -H, with a proviso that when R7 is a heterocyclyl and R8 is
-(C0-C4 alkyl)— NR5R6, a heteroatom of R7 is not bonded to -NR5R6 directly or via a methylene group; R5 and R6 are independently chosen from -H and C1 -C4 alkyl; and
R is chosen from C1-C6 alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl and substituted heteroaryl; with a proviso that when R3 is phenyl and R2 is piperidin-4-yl-ethyl, R1 is not cyclopropyl.
[0011] In another aspect the invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a compound of formula I, or salt thereof.
[0012] In another aspect the invention relates to a method for treating T-cell mediated diseases including autoimmune disease such as rheumatoid arthritis and lupus erythematosus, inflammatory diseases such as asthma and inflammatory bowel disease, cancer such as gastrointestinal cancer, and diabetes. The method comprises administering a therapeutically effective amount of a compound of formula I, or salt thereof.
Detailed Description of the Invention
[0013] In its broadest sense, the invention relates to compounds of the formula I, or salt thereof:
Figure imgf000005_0001
wherein:
R1 is chosen from C1-C4 alkyl, carbocyclyl, substituted carbocyclyl and
Figure imgf000005_0002
wherein
R4 is chosen from cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein R4 may be substituted, with a proviso that when R4 is a heteroaryl, R4 is not bonded via a heteroatom to the methylene carbon bearing the Z group; and Z is chosen from -H and C1 -C4 alkyl;
R2 is chosen from -(C2-C7 alkyl)-NR5R6, -(C0-C4 alkyl)-R7-R8, and -(C0-C4 alkyl)-C(0)-(Co-C4 alkyl)-R7-R8, wherein R7 is cyclyl, with a proviso that when R7 is a heterocyclyl, a purine nitrogen of Formula I bonded to R2 is not bonded to a heteroatom of R7 directly or via a methylene group; R8 is chosen from -(C0-C4 alkyl)-NR5R6, and
-C(O)-(C0-C4 alkyl)-NR5R6, and, when R7 is nitrogenous heterocyclyl, R8 may additionally be -H, with a proviso that when R7 is a heterocyclyl and R8 is -(C0-C4 alkyl)— NR5R6, a heteroatom of R7 is not bonded to -NR5R6 directly or via a methylene group;
R5 and R6 are independently chosen from -H and C1-C4 alkyl; and R is chosen from C1-C6 alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl and substituted heteroaryl; with a proviso that when R3 is phenyl and R2 is piperidin-4-yl-ethyl, R1 is not cyclopropyl.
[0014] In one embodiment, R1 is chosen from C1-C4 alkyl, phenyl optionally substituted with one or two substituents independently chosen from halogen, OCH3, -CF3, -OCF3 and C1-C4
alkyl,
Figure imgf000006_0001
s and wherein
R4 is -(C0-C4 alkyl)-R9, wherein
R9 is chosen from cycloalkyl, aryl, and heteroaryl, wherein R9 is optionally substituted at one or two atoms with substituents independently chosen from halogen, -OH, -OCH3, -CF3, -OCF3, - CN, C1-C4 alkyl, and pyridinyl; and Z is chosen from -H and C1-C4 alkyl.
[0015] In another embodiment, R2 is chosen from -(C2-C7 alkyl)-NR5R6, -(C0-C4 alkyl)-R7-R8, and -(C0-C4 alkyl)-C(O)-(C0-C4 alkyl)-R7-R8,
wherein
R7 is chosen from alicyclyl, nitrogenous alicyclyl, aryl, and nitrogenous heteroaryl; R8 is chosen from -H, -(C0-C4 alkyl)-NR5R6, and
-C(O)-(C0-C4 alkyl)-NR5R6; and R5 and R6 are independently chosen from -H and -(C1-C4 alkyl).
[0016] In another embodiment, R3 is chosen from C1-C6 alkyl, aryl, aryl substituted with R10, R11 and R12,
wherein
R10, R11 and R12 are independently chosen from -H, halogen, -OCH3,
-CF3, -OCF3, -CN, C1-C4 alkyl, -NR13R14, -S(O)1nCH3, -CONHR22, -NHCOR23, -
OR24 and -NHS(O)1nR25; wherein
R13 and R14 are independently chosen from -H and C1-C4 alkyl;
R22, R23 and R24 are one or two substituents independently chosen from -H, C1-C4 alkyl, C1-C6 cycloalkyl, aryl, -(CH2)nNR26R27 and -(CH2)nOR28 said C1-C4 alkyl and C1-C6 cycloalkyl being optionally substituted with one or more halogens; R25 is C1-C4 alkyl;
R26 and R27 are independently chosen from H and C1-C4 alkyl or R26 and R27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O; R28 is chosen from H and C1-C4 alkyl; m is 0 , 1 or 2 and n is 1, 2 or 3.
[0017] In another embodiment, R1 is chosen from C1-C4 alkyl, phenyl optionally substituted with one or two substituents independently chosen from halogen, OCH3, -CF3, -OCF3 and C1-C4
alkyl,
Figure imgf000008_0001
and
Figure imgf000008_0002
wherein
R4 is chosen from
Figure imgf000008_0003
Figure imgf000008_0004
wherein
R15 and R16 are independently chosen from -H, halogen, -OH, -OCH3,
CF3, -OCF3, -CN, C1-C4 alkyl, and pyridinyl;
R17 is chosen from O and S;
R18 is chosen from CH and N;
R19 and R20 are independently chosen from -H, halogen,
-OCH3, -CF3, -OCF3, -CN, C1-C4 alkyl, and pyridinyl; and Z is chosen from -H and C1-C4 alkyl.
[0018] In another embodiment, R2 is chosen from -(C2-C7 alkyl)-NR5R6,
-(C0-C4 alkyl)-R7-R8, and -(C0-C4 alkyl)-C(O)-(C0-C4 alkyl)-R7-R8,
wherein
R7 is chosen from cyclohexyl, phenyl, piperidinyl, pyrrolidinyl, morpholinyl, and piperazinyl; R8 is chosen from -H, -(C0-C4 alkyl)-NR5R6, and
-C(O)-(C0-C4 alkyl)-NR5R6; and R5 and R6 are independently chosen from -H and -(C1-C4 alkyl).
[0019] In another embodiment, R is other than
Figure imgf000009_0001
Figure imgf000009_0002
[0020] In another embodiment, R3 is chosen from C1-C6 alkyl,
Figure imgf000009_0003
, and
Figure imgf000009_0004
wherein
R10, R11 and R12 are independently chosen from -H, halogen, -OCH3,
-CF3, -OCF3, -CN, C1-C4 alkyl, -NR13R14, -S(O)1nCH3, -CONHR22, -NHCOR23,
OR24 and -NHS(O)1nR25; wherein
R13 and R14 are independently chosen from -H and C1-C4 alkyl;
R22, R23 and R24 are one or two substituents independently chosen from -H, C1-C4 alkyl, C1-C6 cycloalkyl, aryl, -(CH2)nNR26R27 and -(CH2)nOR28 said C1-C4 alkyl and C1-C6 cycloalkyl being optionally substituted with one or more halogens; R25 is C1-C4 alkyl;
R26 and R27 are independently chosen from H and C1-C4 alkyl or R26 and R27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O; R28 is chosen from H and C1-C4 alkyl; m is 0 , 1 or 2 and n is 1, 2 or 3.
[0021] In another embodiment R is chosen from pyridyl, thienyl, thiazolyl and furanyl optionally substituted with methyl or halogen.
[0022] In a different embodiment, the invention relates to compounds of the formula I, or salt thereof:
(I)
Figure imgf000010_0001
wherein:
R1 is chosen from straight or branched C1-C4 alkyl, phenyl optionally substituted with one or two substituents independently chosen from halogen, OCH3, -CF3,
-OCF3 and C1-C4 alkyl,
Figure imgf000010_0002
wherein
R4 is -(C0-C4 alkyl)-R9, wherein R9 is chosen from cycloalkyl, aryl, and heteroaryl, wherein R9 is optionally substituted at one or two atoms with substituents independently chosen from halogen, -OH, -OCH3, - CF3, -OCF3, -CN, C1-C4 alkyl, and pyridinyl, with a proviso that when R9 is a heteroaryl, R9 is not bonded via a heteroatom to the methylene carbon bearing the Z group; and Z is chosen from -H and C1 -C4 alkyl;
R2 is chosen from -(C2-C7 alkyl)-NR5R6, -(C0-C4 alkyl)-R7-R8, and -(C0-C4 alkyl)-C(0)-(Co-C4 alkyl)-R7-R8, wherein
R7 is chosen from alicyclyl, nitrogenous alicyclyl, aryl, and nitrogenous heteroaryl, with a proviso that when R7 is a nitrogenous alicyclyl or a nitrogenous heteroaryl, a purine nitrogen of Formula I bonded to R2 is not bonded directly or via a methylene group to a nitrogen of R7; R8 is chosen from, -(C0-C4 alkyl)-NR5R6, and
-C(O)-(C0-C4 alkyl)— NR5R6, and, when R7 is nitrogenous alicyclyl or nitrogenous heteroaryl, R8 may additionally be
-H, with a proviso that when R7 is a nitrogenous alicyclyl or a nitrogenous heteroaryl and R8 is -(C0-C4 alkyl)— NR5R6, a nitrogen of R7 is not bonded directly or via a methylene group to -NR5R6; and
R5 and R6 are independently chosen from -H and -(C1-C4 alkyl); R3 is chosen from C1-C6 alkyl, aryl, aryl substituted with R10, R11 and R12, wherein
R10, R11 and R12 are independently chosen from -H, halogen, -OCH3, -CF3, -OCF3, -CN, C1-C4 alkyl, -NR13R14, -S(O)1nCH3, -CONHR22, -NHCOR23, - OR24 and -NHS(O)1nR25; wherein R13 and R14 are independently chosen from -H and C1-C4 alkyl; R22, R23 and R24 are one or two substituents independently chosen from -H, C1-C4 alkyl, C1-C6 cycloalkyl, aryl, -(CH2)nNR26R27 and -(CH2)nOR28 said C1-C4 alkyl and C1-C6 cycloalkyl being optionally substituted with one or more halogens;
R25 is C1-C4 alkyl;
R26 and R27 are independently chosen from H and C1-C4 alkyl or
R26 and R27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O;
R28 is chosen from H and C1 -C4 alkyl; m is 0 , 1 or 2 and n is 1 , 2 or 3
[0023] In one embodiment, R1 is chosen from C1-C4 alkyl, phenyl optionally substituted with one or two substituents independently chosen from halogen, OCH3, -CF3, -OCF3 and C1-C4
alkyl,
Figure imgf000012_0001
wherein
Figure imgf000012_0002
wherein
R15 and R16 are independently chosen from -H, halogen, -OH, -OCH3,
CF3, -OCF3, -CN, C1-C4 alkyl, and pyridinyl;
R17 is chosen from O and S;
R18 is chosen from CH and N; R19 and R20 are independently chosen from -H, halogen, -OCH3, -CF3, -OCF3, -CN, C1-C4 alkyl, and pyridinyl; and Z is chosen from -H and C1-C4 alkyl.
[0024] In one embodiment, R2 is chosen from -(C2-C7 alkyl)-NR5R6,
-(C0-C4 alkyl)-R7-R8, and -(C0-C4 alkyl)-C(O)-(C0-C4 alkyl)-R7-R8,
wherein
R7 is chosen from cyclohexyl, phenyl, piperidinyl, pyrrolidinyl, morpholinyl, and piperazinyl; R8 is chosen from -H, -(C0-C4 alkyl)-NR5R6, and
-C(O)-(C0-C4 alkyl)-NR5R6; and R5 and R6 are independently chosen from -H and -(C1-C4 alkyl).
[0025] In another embodiment, R is other than
Figure imgf000013_0001
and
Figure imgf000013_0002
[0026] In another embodiment, R is chosen from C1-C6 alkyl,
Figure imgf000013_0003
and
Figure imgf000013_0004
wherein
R10, R11 and R12 are independently chosen from -H, halogen, -OCH3,
-CF3, -OCF3, -CN, C1-C4 alkyl, -NR13R14, -S(O)1nCH3, -CONHR22, -NHCOR23,
> 24
OR24 and -NHS(O)mR 2z5. wherein
R13 and R14 are independently chosen from -H and C1-C4 alkyl; R22, R23 and R24 are one or two substituents independently chosen from -H, C1-C4 alkyl, C1-C6 cycloalkyl, aryl, -(CH2)nNR26R27 and -(CH2)nOR28 said C1-C4 alkyl and C1-C6 cycloalkyl being optionally substituted with one or more halogens;
R25 is C1-C4 alkyl;
R26 and R27 are independently chosen from H and C1-C4 alkyl or
R26 and R27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O;
R28 is chosen from H and C1-C4 alkyl; m is 0 , 1 or 2 and n is 1, 2 or 3.
[0027] In another embodiment R3 is chosen from pyridyl, thienyl, thiazolyl and furanyl optionally substituted with methyl or halogen
[0028] In another embodiment, R1 is
Figure imgf000014_0001
R4
wherein
R4 is chosen from
Figure imgf000014_0002
and
Figure imgf000014_0003
wherein
R15 and R16 are independently chosen from -H, halogen, -OH, -OCH3,
CF3, -OCF3, -CN and C1-C4 alkyl;
R17 is chosen from O and S; R18 is chosen from CH and N; R19 and R20 are independently chosen from -H, halogen, -OCH3, -CF3, -OCF3, -CN, C1-C4 alkyl, and pyridinyl; and is chosen from -H and C1-C4 alkyl.
[0029] In another embodiment, R2 is chosen from
Figure imgf000015_0001
Figure imgf000015_0002
[0030] In another embodiment, R is chosen from
Figure imgf000015_0003
Figure imgf000015_0004
Figure imgf000016_0001
[0031] In another embodiment , R3 is
Figure imgf000016_0002
wherein
R10, R11 and R12 are independently chosen from -H, halogen, -OCH3,
-CF3, -OCF3, -CN, C1-C4 alkyl, -NR13R14, -S(O)1nCH3, -CONHR22, -NHCOR23,
OR24 and -NHS(O)1nR25; wherein
R13 and R14 are independently chosen from -H and C1-C4 alkyl;
R22, R23 and R24 are one or two substituents independently chosen from -H, C1-C4 alkyl, C1-C6 cycloalkyl, aryl, -(CH2)nNR26R27 and
-(CH2)nOR28 said C1-C4 alkyl and C1-C6 cycloalkyl being optionally substituted with one or more halogens;
R25 is C1-C4 alkyl;
R26 and R27 are independently chosen from H and C1-C4 alkyl or
R26 and R27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O;
R28 is chosen from H and C1-C4 alkyl; m is 0 , 1 or 2 and n is 1, 2 or 3.
[0032] In another embodiment R is chosen from pyridyl, thienyl, thiazolyl and furanyl optionally substituted with methyl or halogen. [0033] In yet another embodiment, the invention relates to compounds of the formula I, or salt thereof:
(I)
Figure imgf000017_0001
wherein:
R1 is chosen from C1 -C4 alkyl, phenyl optionally substituted with one or two substituents independently chosen from halogen, OCH3, -CF3, -OCF3 and C1-C4 alkyl,
Figure imgf000017_0002
wherein
R4 is chosen from
Figure imgf000017_0003
Figure imgf000017_0004
wherein
R15 and R16 are independently chosen from -H, halogen, -OH, -OCH3, - CF3, -OCF3, -CN, C1-C4 alkyl, and pyridinyl;
R 17 is chosen from O and S;
R , 1l8δ is chosen from CH and N;
R19 and R20 are independently chosen from -H, halogen,
-OCH3, -CF3, -OCF3, -CN, C1-C4 alkyl, and pyridinyl; and
Z is chosen from -H and C1-C4 alkyl; R2 is chosen from -(C2-C7 alkyl)-NR5R6, -(C0-C4 alkyl)-R7-R8, and
-(C0-C4 alkyl)-C(0)-(Co-C4 alkyl)-R7-R8, wherein
R7 is chosen from cyclohexyl, phenyl, piperidinyl, pyrrolidinyl, morpholinyl, and piperazinyl; R8 is chosen from -H, -(C0-C4 alkyl)-NR5R6, and
-C(O)-(C0-C4 alkyl)-NR5R6; and R5 and R6 are independently chosen from -H and -(C1-C4 alkyl); and R2 contains a basic N atom located from 2 to 8 atoms distant from its point of attachment to the purine ring;
R3 is chosen from C1-C6 alkyl,
Figure imgf000018_0001
and wherein
R10, R11 and R12 are independently chosen from -H, halogen, -OCH3,
-CF3, -OCF3, -CN, C1-C4 alkyl, -NR13R14, -S(O)1nCH3, -CONHR22, -NHCOR23, -
OR24 and -NHS(O)1nR25; wherein
R13 and R14 are independently chosen from -H and C1-C4 alkyl;
R22, R23 and R24 are one or two substituents independently chosen from -H, C1-C4 alkyl, C1-C6 cycloalkyl, aryl, -(CH2)nNR26R27 and
-(CH2)nOR28 said C1-C4 alkyl and C1-C6 cycloalkyl being optionally substituted with one or more halogens;
R25 is C1-C4 alkyl;
R26 and R27 are independently chosen from H and C1-C4 alkyl or
R26 and R27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O;
R28 is chosen from H and C1-C4 alkyl; m is O , 1 or 2 and n is 1 , 2 or 3 [0034] In another embodiment R3 is chosen from pyridyl, thienyl, thiazolyl and furanyl optionally substituted with methyl or halogen.
[0035] When reference is made to a basic N atom, such N atom has a lone pair of electrons available for protonation. N atoms with a basicity below pKb of about 9 are preferred. More preferred are N atoms which exhibit pKb below 7. Such basic N atom may be primary, secondary, or tertiary amine, in linear, branched or cyclic system. Examples of R2 containing basic N atom located from 2 to 8 atoms distant from its point of attachment to the purine ring are:
Figure imgf000019_0001
[0036] In one embodiment, R1 is
Figure imgf000019_0002
R'
wherein
R is chosen from
Figure imgf000019_0003
and
Figure imgf000019_0004
wherein
R15 and R16 are independently chosen from -H, halogen, -OH, -OCH3,
CF3, -OCF3, -CN and C1-C4 alkyl;
R17 is chosen from O and S;
R18 is chosen from CH and N;
R19 and R20 are independently chosen from -H, halogen, -OCH3,
-CF3, -OCF3, -CN, C1-C4 alkyl, and pyridinyl; and is chosen from -H and C1-C4 alkyl.
[0037] In another embodiment, R2 is not
Figure imgf000020_0002
[0038] In another embodiment, R is chosen from
Figure imgf000020_0003
Figure imgf000020_0001
[0039] In another embodiment, R is chosen from
Figure imgf000021_0001
Figure imgf000021_0002
[0040] In another embodiment , R3 is
Figure imgf000021_0003
wherein
R10, R11 and R12 are independently chosen from -H, halogen, -OCH3, -CF3, -OCF3, -CN, C1-C4 alkyl, -NR13R14, -S(O)1nCH3, -CONHR22, -NHCOR23, OR24 and -NHS(O)1nR25; wherein
R13 and R14 are independently chosen from -H and C1-C4 alkyl; R22, R23 and R24 are one or two substituents independently chosen from -H, C1-C4 alkyl, C1-C6 cycloalkyl, aryl, -(CH2)nNR26R27 and -(CH2)nOR28 said C1-C4 alkyl and C1-C6 cycloalkyl being optionally substituted with one or more halogens; R25 is C1-C4 alkyl;
R26 and R27 are independently chosen from H and C1-C4 alkyl or R26 and R27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O; R28 is chosen from H and C1 -C4 alkyl; m is 0 , 1 or 2 and n is 1, 2 or 3.
[0041] In another embodiment R is chosen from pyridyl, thienyl, thiazolyl and furanyl optionally substituted with methyl or halogens.
[0042] In another embodiment is a compound selected from:
(i?)-N-(3-Chloro-4-fluorobenzyl)-8-(2,6-dichlorophenyl)-9-(piperidin-3-ylmethyl)-P/f-purin-2- amine;
(i?)-8-(2,6-Dichlorophenyl)-N-(3-Chloro-4-fluorobenzyl)-9-(piperidin-3-ylmethyl)- 9H- purin-2-amine;
(R)-N- (3-Chloro-6-fluorobenzyl)-8-(2,6-dichlorophenyl)-9-(piperidin-3-ylmethyl)-PH-purin-2- amine;
(i?)-8-(2,6-Dichlorophenyl)-N-(3-fluorobenzyl)-9-(piperidin-3-ylmethyl)-PH-purin-2-amine;
(i?)-8-(2,6-Dichlorophenyl)-N-(2,5-difluorobenzyl)-9-(piperidin-3-ylmethyl)-P/f-purin-2-amine;
(i?)-8-(2,6-Dichlorophenyl)-N-(4-fluorobenzyl)-9-(piperidin-3-ylmethyl)-PH-purin-2-amine;
(i?)-N-(3,4-Dichlorobenzyl)-8-(2,6-dichlorophenyl)-9-(piperidin-3-ylmethyl)-PH-purin-2-amine;
(i?)-N-(3-Chloro-4-fluorobenzyl)-8-(2-chloro-6-fluorophenyl)-9-(piperidin-3-ylmethyl)-P/f- purin-2-amine;
(i?)-8-(2,6-Dichlorophenyl)-N-(2,4-difluorobenzyl)-9-(piperidin-3-ylmethyl)-PH-purin-2-amine;
(i?)-8-(2,6-Dichlorophenyl)-N-(2-fluorobenzyl)-9-(piperidin-3-ylmethyl)-PH-purin-2-amine;
(5)-8-(2,6-Dichlorophenyl)-N-(2-fluorobenzyl)-9-(piperidin-3-ylmethyl)-PH-purin-2-amine;
(i?)-N-benzyl-8-(2,6-dichlorophenyl)-9-(piperidin-3-ylmethyl)-PH-purin-2-amine; (i?)-8-(2-chloro-6-fluorophenyl)-N-(3,4-difluorobenzyl)-9-(piperidin-3-ylmethyl)-P/f-purin-2- amine;
(i?)-8-(2,6-Dichlorophenyl)-N-(thien-3-ylmethyl)-9-(piperidin-3-ylmethyl)-PH-purin-2-amine;
(i?)-N-(3-Chloro-6-fluorobenzyl)-8-(2-chloro-6-fluorophenyl)-9-(piperidin-3-ylmethyl)-PH- purin-2-amine;
(i?)-8-(2,6-Dichlorophenyl)-N-(2-fluoro-1-ethylphenyl)-9-(piperidin-3-ylmethyl)-PH-purin-2- amine;
(i?)-8-(2,6-Dichlorophenyl)-N-(2-fluorobenzyl)-9-(piperidin-3-ylmethyl)-PH-purin-2-amine;
(i?)-8-(2,6-Dichlorophenyl)-N-(3,4-difluorobenzyl)-9-(piperidin-3-ylmethyl)-P/f-purin-2-amine;
(i?)-4-(8-(2,6-Dichlorophenyl)-9-(piperidin-3-ylmethyl)-PH-purin-2yl-amino)methylphenol;
(i?)-3-(8-(2,6-Dichlorophenyl)-9-(piperidin-3-ylmethyl)-PH-purin-2yl-amino)methylphenol;
(i?)-2-fluoro-4-(8-(2,6-Dichlorophenyl)-9-(piperidin-3-ylmethyl)-PH-purin-2yl- amino)methylphenol;
(i?)-8-(2,6-Dichloro-4-hydroxymethylphenyl)-N-(3,4-difluorobenzyl)-9-(piperidin-3-ylmethyl)- PH-purin-2-amine;
(i?)-8-(2,4-Dichloro-6-trifluoromethoxyphenyl)-N-(3,4-difluorobenzyl)-9-(piperidin-3-ylmethyl)- PH-purin-2-amine;
(i?)-8-(2,6-Dichloro-4-ethoxyphenyl)-N-(3,4-difluorobenzyl)-9-(piperidin-3-ylmethyl)-PH-purin- 2-amine;
(i?)-8-(2,6-Dichloro-4-methylphenyl)-N-(3,4-difluorobenzyl)-9-(piperidin-3-ylmethyl)-PH-purin- 2-amine;
(i?)-3,5-dichloro-4-(2-(3,4-difluorobenzyl)amino-9-(piperidin-3-ylmethyl)-PH-purin-8-yl)phenol; (i?)-8-(2,6-Dichloro-4-fluorophenyl)-N-(3,4-difluorobenzyl)-9-(piperidin-3-ylmethyl)-P/f-purin- 2-amine;
(i?)-8-(4-Bromo-2,6-dichlorophenyl)-N-(3,4-difluorobenzyl)-9-(piperidin-3-ylmethyl)-PH-purin- 2-amine;
(i?)-8-(4-Amino-2,6-dichlorophenyl)-N-(3,4-difluorobenzyl)-9-(piperidin-3-ylmethyl)-PH-purin- 2-amine;
(i?)-8-(4-Cyclopropylmethyl-2,6-dichlorophenyl)-N-(3,4-difluorobenzyl)-9-(piperidin-3- ylmethyl)-PH-purin-2-amine;
(i?)-8-(2,6-Dichloro-4-(3-dimethylaminopropyl)phenyl)-N-(3,4-difluorobenzyl)-9-(piperidin-3- ylmethyl)-PH-purin-2-amine;
(i?)-8-(2,6-Dichloro-4-(2-dimethylaminoethyl)phenyl)-N-(3,4-difluorobenzyl)-9-(piperidin-3- ylmethyl)-PH-purin-2-amine;
(i?)-8-(2,6-Dichloro-4-(2-hydroxyethyl)phenyl)-N-(3,4-difluorobenzyl)-9-(piperidin-3-ylmethyl)- PH-purin-2-amine;
(i?)-8-(2,6-Dichloro-4-(3-hydroxy-2-methylpropyl)phenyl)-N-(3,4-difluorobenzyl)-9-(piperidin- 3 -ylmethyl)-PH-purin-2-amine;
(i?)-8-(2,6-Dichloro-4-(2-methoxyethyl)phenyl)-N-(3,4-difluorobenzyl)-9-(piperidin-3- ylmethyl)-PH-purin-2-amine;
(i?)-8-(2,6-Dichloro-4-(3-methoxypropyl)phenyl)-N-(3,4-difluorobenzyl)-9-(piperidin-3- ylmethyl)-PH-purin-2-amine;
(i?)-N-(3,5-Dichloro-4-(2-(3,4-difluorobenzylamino)-9-(piperidin-3-ylmethyl)-P/f-purin-8yl- phenyl acetamide and
(i?)-N-(3,5-Dichloro-4-(2-(3,4-difluorobenzylamino)-9-(piperidin-3-ylmethyl)-P/f-purin-8yl- phenyl-3,3,3-trifluoropropyl amide or a pharmaceutically acceptable salt thereof.
[0043] In one embodiment, the invention is directed to a method of treatment of a T-cell mediated disease comprising administering a therapeutically effective amount of a compound of formula I, or salt thereof. The T-cell mediated disease may be, for example, an autoimmune disease or an inflammatory disease. The autoimmune disease, may be, for example, rheumatoid arthritis or lupus erythematosus. The inflammatory disease may be, for example, asthma or inflammatory bowel disease.
[0044] In another embodiment, the invention is directed to a method of treatment of cancer, such as gastrointestinal cancer, comprising administering a therapeutically effective amount of a compound of formula I, or salt thereof.
[0045] In yet another embodiment, the invention is directed to a method of treatment of diabetes comprising administering a therapeutically effective amount of a compound of formula I, or salt thereof.
Definitions
[0046] Throughout this specification the terms and substituents retain their definitions.
[0047] Alkyl and alkane, unless otherwise specified, are intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof. Lower alkyl refers to alkyl groups of from 1 to 6 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s-and t-butyl and the like. Preferred alkyl groups are those Of C2O or below. Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of from 3 to 8 carbon atoms. Examples of cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbornyl and the like.
[0048] (C1 to Cn) Hydrocarbon includes alkyl, cycloalkyl, alkenyl, alkynyl, aryl and combinations thereof containing only hydrogen and one to n carbons. Examples include vinyl, allyl, cyclopropyl, propargyl, phenethyl, cyclohexylmethyl, camphoryl and naphthylethyl. Saturated (C1 to Cn)hydrocarbon is identical in meaning to (C1 to Cn)alkyl or (C1 to Cn)alkane as used herein. Whenever reference is made to C0-n alkyl, (C0 to Cn)alkyl, or (C0 to Cn)alkane when number of carbon atoms is 0, a direct bond is implied.
[0049] Alkoxy or alkoxyl refers to groups of from 1 to 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof attached to the parent structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to four carbons.
[0050] Fluoroalkyl refers to alkyl residues in which one or more hydrogens have been replaced by fluorine. It includes perfluoroalkyl, in which all the hydrogens have been replaced by fluorine. Examples include fluoromethyl, difluoromethyl, trifluoromethyl, trifluoroethyl and pentafluoroethyl.
[0051] Oxaalkyl refers to alkyl residues in which one or more carbons (and their associated hydrogens) have been replaced by oxygen. Examples include methoxypropoxy, 3,6,9- trioxadecyl and the like. The term oxaalkyl is intended as it is understood in the art [see Naming and Indexing of Chemical Substances for Chemical Abstracts, published by the American Chemical Society, 1(196, but without the restriction of ]|127(a)], i.e. it refers to compounds in which the oxygen is bonded via a single bond to its adjacent atoms (forming ether bonds); it does not refer to doubly bonded oxygen, as would be found in carbonyl groups. Similarly, thiaalkyl and azaalkyl refer to alkyl residues in which one or more carbons has been replaced by sulfur or nitrogen, respectively. Examples include ethylaminoethyl and methylthiopropyl.
[0052] Acyl refers to groups of from 1 to 8 carbon atoms of a straight, branched, cyclic configuration, saturated, unsaturated and aromatic and combinations thereof, attached to the parent structure through a carbonyl functionality. One or more carbons in the acyl residue may be replaced by nitrogen, oxygen or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples include acetyl, benzoyl, propionyl, isobutyryl, t-butoxycarbonyl, benzyloxycarbonyl and the like. Lower-acyl refers to groups containing one to four carbons. [0053] Cyclyl refers to a 3- to 8-membered ring containing 0-3 heteroatoms selected from O, N, or S; a bicyclic 9- or 10-membered ring system containing 0-3 heteroatoms selected from O, N, or S; or a tricyclic 13- or 15-membered ring system containing 0-3 heteroatoms selected from O, N, or S. Cyclyl may be saturated, unsaturated, or aromatic. A carbocyclyl is a cyclyl lacking any heteroatoms. As commonly understood, when referring to cyclyl as a substituent, it is intended that the point of attachment is a ring carbon or heteroatom of the cyclyl group.
[0054] Cyclylalkyl refers to an alkyl residue attached to a cyclyl. As commonly understood, when referring to cyclylalkyl as a substituent, it is intended that the point of attachment is the alkyl group.
[0055] Cycloalkylalkyl refers to an alkyl residue attached to a cycloalkyl. As commonly understood, when referring to cycloalkylalkyl as a substituent, it is intended that the point of attachment is the alkyl group.
[0056] Alicyclyl refers to aliphatic compounds having a carbocyclic ring structure which may be saturated or unsaturated, but may not be a benzenoid or other aromatic system. Alicyclyl may be a 3- to 8-membered ring containing 0-3 heteroatoms selected from O, N, or S; a bicyclic 9- or 10-membered ring system containing 0-3 heteroatoms selected from O, N, or S; or a tricyclic 13- or 15-membered ring system containing 0-3 heteroatoms selected from O, N, or S. A carboalicyclyl is an alicyclyl lacking any heteroatoms. As commonly understood, when referring to alicyclyl as a substituent, it is intended that the point of attachment is a ring carbon or heteroatom of the alicyclyl group.
[0057] Alicyclylalkyl refers to an alkyl residue attached to an alicyclyl. As commonly understood, when referring to alicyclylalkyl as a substituent, it is intended that the point of attachment is the alkyl group.
[0058] Aryl and heteroaryl mean a 5- or 6-membered aromatic or heteroaromatic ring containing 0-3 heteroatoms selected from O, N, or S; a bicyclic 9- or 10-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, or S; or a tricyclic 13- or 14-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, or S. As commonly understood, when referring to aryl as a substituent, it is intended that the point of attachment is a ring carbon of the aryl group (or ring carbon or heteroatom of the heteroaryl). For the purpose of the present invention, aryl and heteroaryl refer to systems in which at least one ring, but not necessarily all rings, are fully aromatic. Thus aromatic 6- to 14- membered carbocyclic rings include, e.g., benzene, naphthalene, indane, tetralin, benzocycloheptane and fluorene and the 5- to 10-membered aromatic heterocyclic rings include, e.g., imidazole, pyridine, indole, isoindoline, thiophene, benzopyranone, thiazole, furan, benzimidazole, quinoline, isoquinoline, tetrahydroisoquinoline, quinoxaline, tetrahydrocarboline, pyrimidine, pyrazine, tetrazole and pyrazole.
[0059] Arylalkyl means an alkyl residue attached to an aryl ring. As commonly understood, when referring to arylalkyl as a substituent, it is intended that the point of attachment is the alkyl group. Examples of arylalkyl are benzyl, phenethyl, phenylpropyl and naphthylethyl. Heteroarylalkyl means an alkyl residue attached to a heteroaryl ring. Examples include, e.g., pyridinylmethyl, pyrimidinylethyl and the like.
[0060] Heterocycle means a cycloalkyl or aryl residue in which from one to three carbons is replaced by a heteroatom selected from the group consisting of N, O and S. The nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. Heterocycles also include spiroheterocycles. It is to be noted that heteroaryl is a subset of heterocycle in which the heterocycle is aromatic. Examples of heterocyclyl residues additionally include piperazinyl, 4-piperidinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinylsulfoxide, thiamorpholinylsulfone, oxadiazolyl, triazolyl and tetrahydroquinolinyl.
[0061] Whenever reference is made to nitrogen attached cyclyl or nitrogenous cyclyl (where cyclyl may be identified as heterocyclyl, alicyclyl, or heteroaryl) such cyclyl contains at least one N atom, but may also contain additional 0-3 heteroatoms selected from O, N, or S. [0062] Aminoalkyl means an amino group bound to a core structure via an alkyl group, e.g., aminomethyl, aminoethyl, aminopenthyl, etc. The alkyl group, as defined above, could be straight or branched and, therefore, an aminoalkyl includes, e.g., -CH2CH2CH(CHS)CH2NH2, - CH2C(CHs)2CH2NH2, etc. Alkylaminoalkyl means a secondary amine bound to a core structure via an alkyl group, e.g., -CH2CH2NHCH3, -CH2CH2CH2NHCH2CH3, etc. Dialkylaminoalkyl means a tertiary amine bound to a core structure via an alkyl group, e.g., -CH2N(CH3)2,
-CH2CH2CH2N(CH3)CH2CH3, etc.
[0063] Substituted alkyl, cyclyl, aryl, cycloalkyl, heterocyclyl etc. refer to alkyl, cyclyl, aryl, cycloalkyl, or heterocyclyl wherein up to three H atoms in each residue are replaced with loweralkyl, halogen, haloalkyl, hydroxy, hydroxymethyl, loweralkoxy, perfluoroloweralkoxy, carboxy, carboalkoxy (also referred to as alkoxycarbonyl), carboxamido (also referred to as alkylaminocarbonyl), sulfonamido, aminosulfonyl, alkylaminosulfonyl, cyano, carbonyl, nitro, amino, alkylamino, dialkylamino, ureido, alkylureido, mercapto, alkylthio, sulfoxide, sulfone, acylamino, amidino, alkylthio, alkylsulfinyl, alkylsulfonyl, phenyl, benzyl, heteroaryl, phenoxy, benzyloxy, or heteroaryloxy.
[0064] The term "halogen" means fluorine, chlorine, bromine or iodine.
[0065] As used herein, reference to "treatment" or "treating" a patient are intended to include prophylaxis. The terms include amelioration, prevention and relief from the symptoms and/or effects associated with these disorders. The terms "preventing" or "prevention" refer to administering a medicament beforehand to forestall or obtund an attack. Persons of ordinary skill in the medical art (to which the present method claims are directed) recognize that the term "prevent" is not an absolute term. In the medical art it is understood to refer to the prophylactic administration of a drug to diminish the likelihood or seriousness of a condition, and this is the sense intended.
Abbreviations
[0066] The following abbreviations and terms have the indicated meanings throughout: Ac = acetyl anh. = anhydrous
ACN = acetonitrile
BNB = 4-bromomethyl-3-nitrobenzoic acid
Boc = t-butyloxy carbonyl
Bu butyl
CBZ = carbobenzoxy = benzyloxycarbonyl
CDI = carbonyl diimidazole
DBU = diazabicyclo[5.4.0]undec-7-ene
DCM = dichloromethane = methylene chloride = CH2Cl2
DEAD = diethyl azodicarboxylate
DIC = diisopropylcarbodiimide
DIEA = N,N-diisopropylethyl amine
DMAP = 4-N,N-dimethylaminopyridine
DMF = N,N-dimethylformamide
DMSO = dimethyl sulfoxide
DVB = 1 ,4-divinylbenzene
EEDQ = 2-ethoxy- 1 -ethoxycarbonyl- 1 ,2-dihydroquinoline
Et ethyl
FCC = flash column chromography
Fmoc = 9-fluorenylmethoxycarbonyl
GC = gas chromatography h = hour(s)
HATU = O-(7- Azabenzotriazol- 1 -yl)- 1 , 1 ,3 ,3 -tetramethyluronium hexafluorophosphate
HOAc = acetic acid
HOBt = hydroxybenzotriazole
Me = methyl mesyl = methanesulfonyl
MTBE = methyl t-butyl ether NMO N-methylmorpholine oxide
PEG polyethylene glycol
Ph or K phenyl
PhOH phenol
PfP pentafluorophenol
PPTS pyridinium p-toluenesulfonate
PyBroP bromo-tris-pyrrolidino-phosphonium hexafluorophosphate rm reaction mixture rt room temperature sat'd saturated
TBDMS t-butyldimethylsilyl
TFA trifluoroacetic acid
THF tetrahydrofuran
TIPSO triisopropylsilanyloxy
TMOF trimethyl orthoformate
TMS trimethylsilyl
TBDMS t-butyldimethylsilyl tosyl p-toluenesulfonyl
Trt triphenylmethyl
[0067] Although this invention is susceptible to embodiment in many different forms, preferred embodiments of the invention are shown. It should be understood, however, that the present disclosure is to be considered as an exemplification of the principles of this invention and is not intended to limit the invention to the embodiments illustrated.
[0068] It may be found upon examination that certain members of the claimed genus are not patentable to the inventors in this application. In this event, subsequent exclusions of species from the compass of applicants' claims are to be considered artifacts of patent prosecution and not reflective of the inventors' concept or description of their invention; the invention encompasses all of the members of the genus (I) that are not already in the possession of the public. [0069] In general, the compounds of the present invention may be prepared by the methods illustrated in the general reaction schemes as, for example, described below, or by modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants that are in themselves known, but are not mentioned here.
General synthesis of purines
[0070] One method for preparing purine analogs of the invention is shown in Scheme 1.
Displacement of the two chlorides in 2,4-dichloro-5-nitropyrimidine 1 usually occurs in a regioselective manner. Thus, the more reactive chloride in the 2-position is first displaced by an amine R5NH2 to yield compound 2. Addition of a second amine R"NH2 displaces the chloride in the 4-position. Reduction of the nitro group in 3 to an amine using reagents well known in the art (e.g. Raney Ni/ H2, Fe/EtOH/aqAcOH, Na2S2θ4/NH4OH/H2θ/Dioxane), followed by cyclization with an aryl aldehyde gives purine 5.
Scheme 1. Synthesis of purine analogs.
Figure imgf000032_0001
reduction N.R,,
Figure imgf000032_0002
[0071] The purine analogs of the invention may be prepared on solid support (Scheme 2).
For example, an acid cleavable linker can be attached to the Argogel-NH2 resin. The resin with the linker is first reductive aminated with a R5NH2. The pyrimidine 2, which is similarly prepared from the first step in Scheme 1, is then attached to the amine by a nucleophilic displacement reaction. Reduction of the nitro group, followed by ring closure with an aldehyde, yields the purine. The product can then be released from the solid support by treatment with acid such as trifloroacetic acid.
Scheme 2. Solid phase synthesis of purine analogs.
Figure imgf000033_0001
Figure imgf000033_0002
Figure imgf000033_0003
[0072] Following are exemplary procedures for preparation of some of the compounds of the invention.
Synthesis ofN-(3,4-difluorobenzyl)-8-(2-chloro-6-fluorophenyl)-9-((R)-piperidin-3-ylmethyl)- 9H-purin-2-amine (Compound 113)
[0073] One possible process for synthesis of N-(3,4-difluorobenzyl)-8-(2-chloro-6- fluorophenyl)-9-((R)-piperidin-3-ylmethyl)-9H-purin-2-amine (Compound 113) is shown in Scheme 3 below and detailed in the following description. Scheme 3.
Figure imgf000034_0001
/ water in DMA,
Figure imgf000034_0003
Figure imgf000034_0002
N-(3,4-dιfluorobenzyl)-8-(2-chloro-6-fluorophenyl)- 14 9-((R)-pιperιdιn-3-ylmethyl)-9H-purιn-2-amιne
113
(S)-tert-butyl 3-((2-chloro-5-nitropyrimidin-4-ylamino)methyl) piperidine-1-carboxylate (12)
[0074] To 1.267 g (6.53 mmol, 1.0 equiv.) of 2,4-dichloro-5-nitropyrimidine (Toronto Research Chemicals) in 8 mL of anhydrous THF at -78 °C was added dropwise a solution of 6.53 mmol (1 equiv.) of an amine and 1.25 mL of JV,iV-diisopropylethylamine in 6.5 mL anhydrous THF.
Figure imgf000034_0004
[0075] The reaction mixture was stirred for 30 min at -78 °C and then allowed to warm to 25 °C and stirred for an additional 1 h. The solvent was removed in vacuo and the residue purified by flash chromatography on silica gel. [0076] (S)-tert-butyl 3-((2-chloro-5-nitropyrimidin-4-ylamino)methyl) piperidine- 1- carboxylate (12):
Figure imgf000035_0001
[0077] was synthesized using the procedure described above, using (S)-1-Boc-3- (aminomethyl) piperidine (1.4 g, 6.53 mmol, CNH Technologies) as the amine. Purification was performed on silica gel, using a 6 / 1 mixture of hexanes / ethyl acetate as the mobile phase. The desired product was obtained as a yellow solid (1.90 g) in 78 % yield. 1H NMR (300 MHz, CDCl3), ppm: 9.05 (s, 1H), 8.56 (br s, 1H), 3.85 (dd, 2H), 3.59 (m, 2H), 3.03 (br t, 1H), 2.87 (dd, 1H), 1.86 (m, 2H), 1.69 (m, 1H), 1.46 (s, 9H), 1.40 (m, 2H, overlapping with 1.46 ppm).
(S)-tert-butyl-3-((2-(3,4-difluorobenzylamino)-5-nitropyrimidin-4-ylamino)methyl) piperidine -I- carboxylate (13)
[0078] To a solution of (S)-teτt-butyl 3-((2-chloro-5-nitropyrimidin-4-ylamino)methyl) piperidine- 1-carboxylate 12 (0.161 g, 0.43 mmol, 1 equiv.) in 2 mL of acetonitrile was added JV,jV-diisopropylethylamine (0.064 g, 0.087 mL, 0.5 mmol, 1.15 equiv.) and 3,4-difluorobenzyl amine (0.068 g, 0.48 mmol, 1.1 equiv.) and the reaction mixture was heated with stirring at 60 °C for 30 min. The solvent was removed in vacuo and the residue was taken in ethyl acetate (30 mL), washed with water (2 x 10 mL) and brine (1 x 10 mL). The organic layer was dried (anhydrous Na2SO4) and concentrated in vacuo. The pale yellow residue was purified by column chromatography (silica gel, hexane / ethyl acetate 3 / 1) to give 0.188 g of desired product 13 (91 % yield). 1H NMR (300 MHz, CDCl3), ppm: 8.80 (s, 1H), 8.60 (br t, 1H), 7.16 (m, 2H), 7.06 (m, 1H), 6.87 (br t, 1H), 4.58 (d, 2H), 3.80 (m, 2H), 3.43 (m, 2H), 2.88 (br, 1H), 2.55 (br, 1H), 1.78 (m, 2H), 1.64 (m, 1H), 1.43 (s, 9H), 1.44 (m, 1H, overlapping with 1.43 ppm), 1.22 (m, 1H) ; MS (EI) m/z 478.8 (MH)+.
(3S)-tert-butyl-3-((2-(3,4-difluorobenzylamino)-8-(2-chloro-6-fluorophenyl)-9H-purin-9- yl)methyl)piperidine-l-carboxylate (14)
[0079] To a solution of 0.522 g (3.0 mmol, 12.5 equiv.) of sodium hydrosulfite in 4 mL of water and 0.2 mL of a saturated aqueous solution of ammonia was added a solution of (S)-tert- butyl 3-((2-(3,4-difluorobenzylamino)-5-nitropyrimidin-4-ylamino)methyl) piperidine -1- carboxylate 13 (0.115 g, 0.24 mmol, 1 equiv.) in 2 mL of 1,4-dioxane. This solution was stirred for 30 min at 25 °C, when TLC analysis showed no starting material was left. Ethyl acetate (100 mL) was added and the organic layer washed with water (3 X 30 mL) and brine (1 X 30 mL), dried (anhydrous Na2SO4) and concentrated in vacuo to give crude (S)-teτt-butyl 3-((2-(3,4- difluorobenzylamino)-5-aminopyrimidin-4-ylamino)methyl)piperidine-1-carboxylate.
[0080] To a solution of crude (S)-tert-butyl 3-((2-(3,4-difluorobenzylamino)-5- aminopyrimidin-4-ylamino)methyl)piperidine-1-carboxylate in 2 mL of anhydrous N1N- dimethylacetamide and 0.2 mL of acetic acid in a 20 mL scintillation vial was added 2-chloro-6- fluorobenzaldehyde (0.076 g, 0.48 mmol, 2 equiv.). The reaction mixture was heated at 120 °C for 21 h, then allowed to cool to 25 °C. The solution was diluted with ethyl acetate (60 mL), the organic layer was washed with water (2 x 20 mL) and brine (1 x 20 mL), dried (anhydrous Na2SO4) and concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane / ethyl acetate 3 / 2) to give the desired product 14 (0.056 g, 39 % yield over 2 steps). 1H NMR (300 MHz, CDCl3), ppm: 8.75 (s, 1H), 7.54-7.46 (m, 1H), 7.39-7.36 (m, 1H), 7.23-7.06 (m, 4H), 5.74 (br t, 1H), 4.65 (d, 2H), 3.84-3.74 (m, 4H), 2.72 (m, 1H), 2.45 (ddd, 1H), 1.86 (br, 1H), 1.51-1.23 (m, 3H, overlapping with 1.36 ppm), 1.36 (s, 9H), 0.91 (m, 1H); MS (EI) m/z 587.0 (MH)+. N-(3,4-difluorobenzyl)-8-(2-chloro-6-fluorophenyl)-9-((R)-piperidin-3-ylmethyl)-9H-purin-2- amine (113)
[0081] To a solution of 0.0214 g (0.036 mmol) of (35)-tert-butyl 3-((2-(3,4- difluorobenzylamino)-8-(2-chloro-6-fluorophenyl)-9H-purin-9-yl)methyl)piperidine-1- carboxylate 14 in 0.5 niL methylene chloride was added TFA (0.5 rnL) with stirring at room temperature for 1 h. The solvent was removed in vacuo and the residue purified using preparative HPLC to give 0.0212 g (97 % yield) of desired product 113 (TFA salt) as a colorless oil. 1U NMR (300 MHz, CD3OD), ppm: 8.82 (s, 1H), 7.69-7.61 (m, 1H), 7.48-7.45 (m, 1H), 7.35-7.27 (m, 2H), 7.19-7.14 (m, 2H), 4.72-4.58 (m, 2H), 4.05-3.79 (m, 2H), 3.26-3.09 (m, 4H), 2.72-2.52 (m, 2H), 2.13 (br, 1H), 1.86-1.73 (m, 1H), 1.69 (m, 2H), 1.01 (m, 1H) ); MS (EI) m/z 487.2 (MH)+.
Solid Phase Synthesis of Purines
[0082] One possible process for solid phase synthesis of purine analogs of the invention is demonstrated in Scheme 4 below and detailed in the following description.
Scheme 4.
Figure imgf000038_0001
r^^NBoc
0.5 M Na2S2O4, NH4OH HN
1. R3CHO
H2O / dioxane NH,
DMA, 5% CH3COOH, 100 °C, 2 cycles 25 °C, 2 cycles
-L vV 2. aerial oxidation
19
Figure imgf000038_0002
20 21
Step 1 : Reductive animation with a primary amine
[0083] To a 100 mL shaking vessel containing a suspension of 1.2 g (0.786 mmol/g, 0.943 mmol, 1 equiv.) of resin-bound o-methoxybenzaldehyde resin 16 in 10 mL of 1 ,2-dichloroethane (DCE) was added 7.54 mmol (0.4 M, 8.0 equiv.) of an amine. The resin suspension was shaken for 1 min and 1.6 g (7.54 mmol, 0.4 M, 8.0 equiv.) of sodium triacetoxyborohydride was added followed by 10 mL of 1,2-dichloroethane. The suspension was shaken for 16 h at 25 °C. The shaking vessel was then drained, and the resin was washed with CH3OH (IX), CH2Cl2 (2X), CH3OH (IX), CH2Cl2 (2X), CH3OH (IX), CH3OH (1X30 min) and CH2Cl2 (2X). The resulting resin-bound secondary amine 17 gave a positive result with the bromophenol blue staining test. The resin was dried in vacuo.
Step 2: N-arylation with a 4-amino-2-chloro-5-nitropyrimidine
[0084] To 1.2 g (0.786 mmol/g, 0.943 mmol, 1 equiv.) of resin-bound secondary amine 17 in 4 mL of DMF and 0.33 mL (0.244 g, 1.886 mmol, 2.0 equiv.) of JV,JV-diisopropylethylamine in a shaking vessel was added a solution of 1.886 mmol (0.7 g, 0.25 M, 2.0 equiv.) of (S)-tert-butyl 3-((2-chloro-5-nitropyrimidin-4-ylamino)methyl) piperidine-1-carboxylate in 3.54 mL of DMF. The mixture was shaken at 25 °C for 16 h. The skaking vessel was drained and the resin was washed with DMF (2X), CH2Cl2 (IX), DMF (IX), CH2Cl2 (2X), CH3OH (2X) and CH2Cl2 (2X). The resulting resin-bound nitropyrimidine resin 18 gave a negative result with the bromophenol blue staining tests. The resin was dried in vacuo.
Step 3: Reduction of the nitro group
[0085] To a solution of 5.22 g (30.0 mmol, 0.5 M, 45 equiv.) of sodium hydrosulfite in 40 mL of water was added 20 mL of 1 ,4-dioxane followed by 0.93 mL of a saturated aqueous solution of ammonia. This solution was added to a 100 mL shaking vessel containing 1.2 g (0.786 mmol/g. 0.943 mmol, 1 equiv.) of resin-bound 5 -nitropyrimidine 18. The resin suspension was shaken for 2 h at 25 °C. The shaking vessel was drained and the resin was washed with water: 1,4-dioxane 2:1 (v/v) (IX). The shaking vessel was recharged with 60 mL of a freshly prepared 0.5 M solution of sodium hydrosulfite in 40 mL of water and 20 mL of dioxane and 0.93 mL of a saturated aqueous solution of ammonia that was prepared as described above. The suspension was shaken at 25 °C for 16 h. The shaking vessel was drained and the resin was washed with water: 1,4-dioxane 2:1 (v/v) (2X), anhydrous CH3OH (2X), anhydrous DMF (2X), CH2Cl2 (2X) and anhydrous THF (2X). The resulting resin-bound 5-aminopyrimidine 19 gave a positive result with the bromophenol blue staining test. The resin was dried in vacuo.
Step 4: Purine formation
[0086] To a 20 rnL scintillation vial containing 200 mg (0.786 mmol/g resin, 0.157 mmol, 1.0 equiv.) of the resin-bound 5-aminopyrimidine 19 was added 2 mL of a solution of 10.8 mmol (0.9 M, 12.5 equiv.) of an aldehyde in 10.8 mL of anhydrous JV,iV-dimethylacetamide and 0.2 mL of acetic acid. The resin suspension was heated at 100 °C for 21 h, then allowed to cool to 25 °C. The solution was removed via pipette and the resin was washed with anhydrous N1N- dimethylacetamide (2X). The vial was recharged with 2.0 mL of a solution of 10.8 mmol (0.9 M, 12.5 equiv.) of the same aldehyde in 10.8 mL of JV,iV-dimethylacetamide and 0.2 mL of acetic acid. The resin suspension was heated at 100 °C for 16 h, then allowed to cool to 25 °C and transferred to a small shaking vessel. The vessel was drained and the resin was washed with DMF (4X), CH2Cl2 (2X), CH3OH (2X) and CH2Cl2 (2X). The resulting resin-bound purine 20 was dried in vacuo.
[0087] Typical acid cleavage conditions were employed by stirring the resin in 10 mL of a 1 : 1 mixture of CH2Cl2 / TFA (v/v) for 1 hour at 25 °C. The resin suspension was then transferred to a small shaking vessel. The vessel was drained and the resin washed with CH2Cl2 (3X). Preparative HPLC purification of the combined filtrate gave the desired purine 21 (TFA salt). (^-S-fl^-dichlorophenyπ-g-fpiperidin-S-ylmethyπ-N-fthiophen-1-ylmethyπ-gH-purin-1-amine (119)
[0088] (R)-8-(2,6-dichlorophenyl)-9-(piperidin-3-ylmethyl)-N-(thiophen-2-ylmethyl)-9H- purin-2-amine (119):
Figure imgf000041_0001
was prepared according to the above given procedure. 7.54 mmol (0.853 g, 0.4 M, 8.0 equiv.) of thiophene-2-methylamine were used in the step of reductive amination of resin with a primary amine. For the step of purine formation, the resin (1.2 g, 0.786 mmol/g, 0.943 mmol) was equally divided into 6 vials. In each vial, 2 mL of a solution of 10.8 mmol (0.9 M, 12.5 equiv.) of 2,6-dichloro benzaldehyde in 10.8 mL of anhydrous JV,iV-dimethylacetamide and 0.2 mL of acetic acid were added to 200 mg of resin-bound 5-aminopyrimidine (0.786 mmol/g, 0.157 mmol). Final preparative HPLC purification gave 160 mg of desired compound TFA salt as a colorless oil. The TFA salt was converted into the HCl salt by adding portions of 20 mL of a 1 M solution of HCl in ethanol (Alfa Aesar), stirring for 15 min at room temperature and in vacuo removing the solvent. The procedure was repeated 5 times. The sample was triturated with ether to give a light yellow solid, that recrystallized from methylene chloride / hexanes as a white solid (105 mg after being dried for 16 h over P2O5 under high vacuum at 40 °C). HCl salt: 1H NMR (300 MHz, CD3OD), ppm: 8.89 (s, 1H), 7.66 (m, 3H), 7.31 (m, 1H), 7.12 (br s, 1H), 6.97 (m, 1H), 4.92 (m, 2H), 3.98 (m, 2H), 3.85 (dd, 2H), 2.73 (m, 2H), 2.25 (br, 1H), 1.80 (m, 1H), 1.60 (m, 2H), 1.21 (m, 1H) ); MS (EI) m/z 473.1 (M)+.
Synthesis of (N)-(2-Chlorobenzvπ-8-ethyl-9-(2-(peperidin-4-vπethvπ-9/f-purin-2-amine (477) [0089] One possible process for solid phase synthesis of compound 477 is demonstrated in Scheme 5 below and detailed in the following description.
Scheme 5.
/-PA / 30% aq NaOH
Figure imgf000042_0001
Figure imgf000042_0003
Figure imgf000042_0002
22 24 477
[0090] Intermediate 22 is similarly prepared by using the same solid phase method to prepare compound 19. Propionyl chloride (0.14 mL, 10 equiv.) was added to solid phase intermediate 22 (0.2 g, 0.8 mmol/g, O.lβmmol) suspended in pyridine (2 mL) and DCM (1 mL) in a small shaker vessel that was shaken for 16 h at 25 °C. The vessel was drained and the resins were washed with DCM (2X), MeOH (2X), DMF (IX), MeOH (2X) and DCM (2X). The resulting resin- bound amide gave a negative result with a bromophenol blue staining test.
[0091] The above amide was suspended in z-PA (1.5 mL) and transferred to a 20 mL scintillation vial. A 30% aq solution of NaOH (1 mL) was added and the mixture was slowly stirred at 80 °C for 16 hr and allowed to cool. The solution was removed via pipette and then recharged with z-PA (1.5 mL) and 30% aq NaOH (1 mL) and heated at 80 °C for 18 hr. The cooled mixture was transferred back to a small shaking vessel, drained and the resins were rinsed with 1-PAZH2O (2:1, 2X), MeOH (2X), DCM (IX), MeOH (2X) and DCM (2X).
[0092] The resulting resin-bound 8-ethyl purine derivative was cleaved from the resin following the typical acid cleavage procedure and purified via preparative RP-HPLC to yield the titled compound 477 (3.1 mg) as a TFA salt: 1H NMR (300 MHz, CD3OD), ppm: 8.64 (s, 1H), 7.47 (m, 2H), 7.30 (m, 2H), 4.81 (m, 2H), 4.20 (dd, 2H), 3.36(m, 2H), 3.00 (q, 2H), 2.90 (m, 2H), 1.99 (d, 2H), 1.74 (q, 2H), 1.60 (m, 2H), 1.45 (t, 3H) ); MS (EI) m/z 399.1/40.2 (M)+.
Further Alternative synthesis of purines
1. One alternative process for preparing purine analogs of the invention is shown in Scheme 4. Variation of the Rl -position on the purine scaffold could be accomplished by substitution of a SO2Me-group at the Rl -position. By using this route (Scheme 6), variation is introduced in a later stage of the synthesis compared with the route given in Scheme 1. As given in Scheme 1, displacement of the two chlorides in 2,4-dichloro-5-nitropyrimidine 1 usually occurs in a regioselective manner. Thus, the more reactive chloride in the 2-position is first displaced by an amine R'NH2 to yield compound 2. Addition of NaSMe displaces the chloride in the 4-position. Reduction of the nitro group in 25 to an amine (26) using reagents well known in the art (e.g. Na2S2θ4/NH4θH/H2O/dioxane, Pd(C)/H2/MeOH), followed by cyclization with an aryl aldehyde gives purine 27. Oxidation of the MeS-substituent to the corresponding sulfone and replacement of this leaving group with an amine gives the substituted purine 5.
Scheme 6. Synthesis of purine analogs: variation of Rl by substitution of sulphon.
Figure imgf000043_0001
cyclization -AT
Figure imgf000043_0002
28 27
The following is an exemplary procedure for preparation of some of the compounds of the invention. Synthesis of (RV4-((8-(2.6-dichlorophenylV9-(piperidin-3-ylmethylV9H-purin-2-yl- amino)methyl)-2-fluorophenol 2,2,2-trifluoroacetate (compound 506)
One possible process for synthesis of (R)-4-((8-(2,6-dichlorophenyl)-9-(piperidin-3-ylmethyl)- 9H-purin-2-ylamino)methyl)-2-fluorophenol 2,2,2-trifluoroacetate (506) is shown in Scheme 7 below and detailed in the following description.
Scheme 7.
Na2S2O4, aq NH3, dioxane, rt o n
46% yield
Figure imgf000045_0001
12 29
DCM
Figure imgf000045_0003
°C 62% yield
Figure imgf000045_0004
Figure imgf000045_0005
Synthesis of compound 12 has been described previously (Scheme 3).
Compound 29
To a solution of compound 12 (24.85 g, 66.8 mmol, 1.0 equiv.) in DMF (70 ml), was added NaSMe (5.15 g, 73.5 mmol, 1.1 equiv.), resulting in a orange suspension. This was stirred at rt for 2 h. After observing complete conversion by NMR of the mixture, the mixture was diluted with EtOAc and washed with water (3x) followed by washing with brine. The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. 23.93 g of solid compound 29 was obtained in 93% yield.
Compound 30
To a solution of compound 29 (23.93 g, 62.4 mmol, 1.0 equiv.) in dioxane (100 ml), a saturated solution Of Na2S2O4 (50 g, 287 mmol, 4.6 equiv.) in water was added followed by aq. NH3 (10 ml). Reaction mixture was stirred at rt o.n.. The mixture was diluted with EtOAc and washed with water (4x) and brine. The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. 10.25 g of compound 30 was obtained as a off-white solid in 46% yield.
Compound 31
To a solution of compound 30 (10.25 g, 29 mmol, 1.0 equiv.) in DMA (100 ml) was added 2,6- dichlorobenzaldehyde (7.6 g, 43 mmol, 1.5 equiv.) followed by AcOH (10 ml). The mixture was heated at 14O°C while air was bubbled through for 36 h. The mixture was then diluted with EtOAc and washed with water (3x) followed by brine. The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. The crude product was purified over silica, using a 1 :1 EtO Ac/heptane mixture as mobile phase. 5.39 g of yellow solid 31 was obtained in 36% yield.
Compound 32
To a solution of compound 31 (4.3 g, 8.46 mmol, 1.0 equiv.) in DCM at O°C, m-CPBA (70%, 4.4 g, 17 mmol, 2.0 equiv.) was added. The mixture was allowed to warm to rt slowly and was stirred for 3 h. Mixture was then diluted with DCM and washed with NaHCO3 (2x), followed by water (2x) and brine. The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. Compound 32 was obtained in near quantitative yield (4.56 g) as a colorless solid. Compound 33
To a solution of compound 32 (0.185 mmol, 100 mg, 1.0 equiv.) in NMP (2 ml) was added 3- fluoro-4-methoxybenzylamine (1.850 mmol, 287 mg, 10 equiv.). The reaction mixture was heated to 100 °C and stirred overnight. Mixture was then poured into H2O and extracted with
EtOAc. The combined organic layers were washed with water and brine, dried (Na2SC>4), filtered and concentrated in vacuo. 70 mg of compound 33 was obtained in 62% yield.
(R)-4-((8-(2,6-dichlorophenyl)-9-(piperidin-3-ylmethyl)-9H-purin-2-ylamino)methyl)-2- fluorophenol 2,2,2-trifluoroacetate (506)
To a solution of compound 33 (0.065 mmol, 40 mg, 1.0 equiv.) in DCM (2 ml) was added BBr3 (0.182 mmol, 0.018 ml, 45.6 mg, 2.8 equiv.). The reaction mixture was stirred overnight at rt. For workup, the reaction mixture was cooled to 0 °C and quenched with MeOH. This solution was concentrated in vacuo and purified by semi-prepHPLC (0% to 80% ACN with TFA). After lyophilizing compound 506 was obtained as the TFA-salt in 60% yield (40 mg). TFA-salt: 1H NMR (400 MHz, CDCl3), ppm: 10.40 (br s, 1H), 9.39 (br s, 1H), 8.67 (s, 1H), 7.53 (m, 3H), 7.31 (m, 1H), 7.29 (m, 1H), 7.13 (dd, 1H), 7.04 (m, 2H), 4.56 (dd, 2H), 3.84 (m, 1H), 3.73 (m, 1H), 3.40 (t, 1H), 3.25 (m, 1H), 2.73 (m, 1H), 2.64 (m, 1H), 2.42 (m, 1H), 2.04 (m, 1H), 1.57 (m, 1H), 1.26 (m, 1H), 0.89 (m, 1H).
2. Another possible route for preparing purine analogs of the invention is shown in Scheme 8. Introduction of substituted anilines on the Rl -position of the purine scaffold could be accomplished by substituting a chloride under more vigorous conditions. Further synthesis to obtain the purine analogs of the invention can be achieved by folio win the reaction steps given in earlier routes (reduction and cyclization, see also Scheme 1 and 3). Scheme 8.
Figure imgf000048_0001
The following is an exemplary procedure for the preparation of a compound of the invention.
Synthesis of (^-S-fl^-dichlorophenyπ-N-QΛ-dichlorophenyπ-g-fpiperidin-S-ylmethyl)-gH- purin-2-amine 2,2,2-trifluoroacetate (compound 720)
One possible process for synthesis of (R)-8-(2,6-dichlorophenyl)-N-(3,4-dichlorophenyl)-9- (piperidin-3-ylmethyl)-9H-purin-2-amine 2,2,2-trifluoroacetate (720) is shown in Scheme 9 below and detailed in the following description.
Scheme 9.
CI
Figure imgf000049_0001
12 35 yield
Figure imgf000049_0002
36
TFA, DCM rt, 1 5 h 25 % yield
Figure imgf000049_0003
The synthesis of compound 12 is also described in Scheme 3 and detailed in the procedure below Scheme 3.
Compound 35
To a solution of compound 12 (100 mg, 0.269 mmol, 1.0 equiv.) in ACN (3 ml), was added DIEA (54 μl, 0.309 mmol, 1.15 equiv.) and 3,4-dichloroaniline (55.7 mg, 0.344 mmol, 1.28 equiv.). The reaction mixture was stirred at 80 °C for 4 h. TLC showed that the reaction was complete. For workup, the rm was concentrated in vacuo, dissolved again in EtOAc, washed with water (twice) and brine. The crude product was concentrated again, purified over silica (eluens heptEtOAc to 6:4). Product fractions were collected and concentrated in vacuo to obtain compound 35 in 87% yield.
Compound 36
To a solution OfNa2S2O4 (512 mg, 2.94 mmol, 12.5 equiv.) in water (2 ml) and ammonia (aqueous sol, 189 μl, 4.23 mmol, 18.0 equiv.) was added a solution of compound 35 in dioxane (1 ml). The rm was stirred at rt for 2.5 h. After completion, EtOAc was added to the rm, followed by washing with water (3x) and brine. After drying on Na2SO4, filtration and concentration in vacuo, crude compound 36 was obtained in 100% yield.
Compound 37
To a solution of compound 36 (110 mg, 0.235 mmol, 1.0 equiv.) in DMA (2 ml) was added 2,6- dichlorobenzaldehyde (82 mg, 0.471 mmol, 2.0 equiv.) and acetic acid (0.2 ml). The reaction mixture was stirred o.n. in a sealed tube at 120 °C. After completion, the r.m. was cooled down to rt, diluted with EtOAc and washed with H2O (3x) and brine. After drying on Na2SO4, filtration and concentration in vacuo, the crude product was purified by column chromatography (heptEtOAc 9:1 to 1 :1). Product fractions were collected and concentrated in vacuo to obtain compound 37 in 42 % yield (62 mg).
(R)-8-(2,6-dichlorophenyl)-N-(3,4-dichlorophenyl)-9-(piperidin-3-ylmethyl)-9H-purin-2-amine 2,2,2-trifluoroacetate (720)
To a solution of compound 37 (62 mg, 0.10 mmol) in DCM (1.5 ml) was added TFA (0.5 ml). The rm was stirred for 1.5 h at rt. The reaction mixture was concentrated in vacuo. After purification by prep-HPLC (0-70 % ACN/TFA, 2x) and lyophilization, compound 720 was obtained as the TFA-salt in 25 % yield (16 mg). Compounds 513, 520, 522 and 530 (Scheme 10) can be synthesized using the synthetic route described in Scheme 1. The required aldehydes can be prepared according to literature procedures (Synthesis, 2004, no. 12, pp. 2062-2065).
Scheme 10.
Figure imgf000051_0001
513 520
Figure imgf000051_0002
Compound 38 can be converted to ether derivatives (e.g. compound 519) as shown in Scheme 11.
Scheme 11
Figure imgf000051_0003
The following is an exemplary procedure for the preparation of a compound of the invention.
Synthesis of (^-S-fl^-dichloro^-ethoxyphenyπ-N-QΛ-difluorobenzyl)-g-fpiperidin-S- ylmethyl)-9H-purin-2-amine 2,2,2-trifluoroacetate (compound 519)
One possible process for synthesis of (R)-8-(2,6-dichloro-4-ethoxyphenyl)-N-(3,4- difluorobenzyl)-9-(piperidin-3-ylmethyl)-9H-purin-2-amine 2,2,2-trifluoroacetate (519) is shown in Scheme 12 below and detailed in the following description.
vBr
Figure imgf000052_0001
Scheme 12.
Compound 41
To a solution of compound 38 (50 mg, 0.081 mmol, 1.0 equiv.) in NMP (1 ml) was added sodium hydride (9.68 mg, 0.242 mmol, 3.0 equiv.). The rm was stirred for 30 min at rt, then 1- bromoethane (0.030 ml, 0.404 mmol, 5.0 equiv.) was added. Rm was stirred at rt for 5 h to completion. For workup, the reaction mixture was poured out in water and extracted twice with EtOAc. Combined organic layers were washed with water (3x) and brine, dried on Na2SO4, filtered and concentrated in vacuo to obtain the crude compound 41 in a quantitative yield.
(R)-8-(2,6-dichloro-4-ethoxyphenyl)-N-(3,4-difluorobenzyl)-9-(piperidin-3-ylmethyl)-9H-purin- 2 -amine 2,2,2-trifluoroacetate 519 To a solution of compound 41 (52 mg, 0.080 mmol) in DCM (1 ml) was added TFA (0.5 ml). Rm was stirred at rt for 30 min. After completion, the rm was concentrated in vacuo, purified by prep-HPLC (0-50% ACN with TFA), concentrated and lyophilized to obtain the TFA-salt of compound 519 in a 56% yield over two steps.
TFA-salt: 1H NMR (400 MHz, DMSO-D6), ppm: 8.74 (s, 1H), 8.58 (d, 1H), 8.25 (m, 1H), 7.92 (br s, 1H), 7.44 (m, 1H), 7.38 (m, 1H), 7.31 (m, 2H), 7.24 (m, 1H), 4.55 (m, 2H), 4.17 (q, 2H), 3.85 (dd, 1H), 3.70 (dd, 1H), 3.16 (d, 1H), 3.08 (d, 1H), 2.67 (m, 1H), 2.58 (m, 1H), 2.14 (br s, 1H), 1.63 (d, 1H), 1.37 (m, 5H), 1.01 (m, 1H).
3. A possible synthetic route towards compounds of the invention in which R3 is an ortho- monochloroaryl with an amide at the /?αra-position is described in the scheme below (Scheme 13.). Commercially available acid 42 can be first reduced and subsequently reoxidized to aldehyde 44. After ringclosing reaction to the substituted purines, the bromide can be transformed to the acid which can be functionalized to e.g. an amide by procedures well known in the art (e.g. R-NH2/TBTU/DIEA/DCM).
Scheme 13.
reduction oxidation
Figure imgf000053_0001
The following is an exemplary procedure for the preparation of a compound of the invention.
Synthesis of 3-chloro-N-cvclohexyl-4-(2-(3,4-difluorobenzylamino)-9-((R)-piperidin-3- ylmethvD-9H-purin-8-yl)benzamide 2,2,2-trifluoroacetate (629) One possible process for the synthesis of 3-chloro-N-cyclohexyl-4-(2-(3,4- difluorobenzylamino)-9-((R)-piperidin-3-ylmethyl)-9H-purin-8-yl)benzamide (629) is shown in Scheme 14 below and detailed in the following description. Compound 13 is prepared in accordance with syntheses described before (Scheme 3 and corresponding procedures).
Scheme 14.
Figure imgf000054_0001
42 43 44
Figure imgf000054_0002
Compound 43
To a -10 °C cooled solution of 4-bromo-2-chlorobenzoic acid 42 (14.4 g, 61 mmol, 1.0 equiv.) in THF (280 ml) was added dropwise a 1 M solution of BH3 THF (91.4 ml, 1.5 equiv.), temperature was maintained at -10 °C. The reaction mixture was stirred overnight to reach room temperature. For workup, the mixture was added carefully to a solution OfK2COs (4 g) in water (500 ml). The solution was stirred 15 minutes and concentrated in vacuo. The remaining water layer was diluted with EtOAc, washed with 1 N HCl and brine, dried on Na2SO4, filtered and concentrated in vacuo to obtain compound 43 in 68% yield (9.2 g, 41.5 mmol).
Compound 44
Oxalylchloride (6.9 g, 54 mmol, 1.3 equiv.) was dissolved in DCM (153 ml) and cooled to -78 °C. To the cooled solution was a solution of DMSO ( 4.72 ml, 66.5 mmol, 1.6 equiv.) in DCM (57 ml) added dropwise and stirred for 15 minutes at -78 °C. Compound 43 (9.2 g, 41.5 mmol, 1.0 equiv.) was dissolved in DCM (116ml) and added dropwise while the temperature was maintained at -78 °C. The r.m. was stirred for 2 h at -78 °C. Then TEA (28.7 ml, 207 mmol, 5 equiv.) was added and the mixture was allowed to reach room temperature. After stirring for 30 minutes at r.t., the reaction mixture was diluted with 300 ml DCM and washed with saturated NH4C 1, brine, dried on Na2SO4, filtered and concentrated in vacuo. Compound 44 was obtained in 96 % yield (8.8 g).
Compound 48
To a solution of compound 13 (9 g, 0.020 mmol, 1.0 equiv.) in DMA (175 ml) was added compound 44 (8.8 g, 0.040 mmol, 2.0 equiv.) and acetic acid (17.5 ml). The reaction mixture was heated to 140 °C and stirred overnight while air was bubbled through. After 48 h the r.m. was cooled to r.t., diluted with EtOAc and extracted with water (5x), brine (2x), dried on Na2SO4, filtered and concentrated in vacuo. After purification by column chromatography (1 : 1 heptane: EtOAc), compound 48 was obtained in a 23 % yield (3.0 g).
Compound 49
To a mixture of KOAc (2.4 g, 24 mmol, 4.0 equiv.), Pd(OAC)2 (148 mg, 0.66 mmol, 0.11 equiv.), and dppf (1.42 g, 2.56 mmol, 0.43 equiv.) under N2-atmosphere, a solution of compound 48 (3.9 g, 6 mmol, 1.0 equiv.) in DMSO (110 niL) was added. By use of a gas balloon filled with CO(g) and a vacuum pump, the reaction mixture was kept under CO-atmosphere. The mixture was heated at 80 °C for 16 h. After cooling to r.t. and neutralizing by 0.5 M HCl, the product was extracted with DCM and washed with water (4x) and brine. After drying on Na2SO4, filtering and concentration in vacuo, the crude product was purified by column chromatography (5:95 MeOH:DCM to wash away impurities, 1 :5:94 AcOH:MeOH:DCM to elute the product). After concentrating productfractions in vacuo, the product was coevaporated with toluene. Compound
49 was obtained in 40% yield.
Compound 50
To a solution of compound 49 (40 mg, 0.065 mmol, 1.0 equiv.) in DCM (1 ml) was added a prestirred solution (r.t., 10 min.) of DIEA (0.057 ml, 0.33 mmol, 5.0 equiv), TBTU (31 mg, 0.098 mmol, 1.5 equiv.) and aminocyclopentane (0.019 ml, 0.20 mmol, 3.0 equiv.) in DCM (2 ml). R.m. was sitrred at r.t. for 72 h.
R.m was poured out in sat. NaHCO3 and extracted with EtOAc (2x). After washing with brine, drying on Na2SO4, filtering and concentrating in vacuo, crude compound 50 was obtained in 88 % yield.
3-chloro-N-cyclohexyl-4-(2-(3,4-difluorobenzylamino)-9-((R)-pipeήdin-3-ylmethyl)-9H-puήn-8- yljbenzamide 2,2,2-trifluoroacetate (629)
To a solution of compound 50 (45 mg, 0.065 mmol) in DCM (1 ml) was added TFA (0.5 ml). The reaction mixture was stirred at rt for 30 min. Rm was concentrated in vacuo and purified by prep-HPLC (0-50% ACN, with TFA). Productfractions were concentrated and lyophilized in ACN/H2O to obtain the TFA-salt of compound 629 in 79 % yield (36 mg). TFA-salt: 1H NMR (400 MHz, DMSO-D6), ppm: 8.70 (s, 1H), 8.53 (d, 1H), 8.50 (br s, 1H), 8.16 (s, 1H), 8.00 (d, 1H), 7.94 (br s, 1H), 7.78 (s, 1H), 7.75 (s, 1H), 7.43 (m, 1H), 7.37 (m, 1H), 7.24 (m, 1H), 4.53 (m, 2H), 3.91 (m, 1H), 3.81 (m, 1H), 3.70 (m, 1H), 3.11 (d, 1H), 2.95 (d, 1H), 2.62 (m, 1H), 2.45 (m, 1H), 2.04 (br s, 1H), 1.84 (m, 2H), 1.76 (m, 2H), 1.62 (m, 2H), 1.34 (m, 6H), 1.15 (m, 1H), 0.95 (m, 1H).
4. Another possible synthetic route towards compounds of the invention in which R3 is an ort/zo-monochloroaryl with an amide at the /?αrα-position is described in the scheme below (Scheme 15.).
The nitrogroup of 55 can be reduced by procedures well known in the art (e.g. Raney Ni). The primary amine can be functionalized to e.g. a reversed amide by procedures well known in the art (e.g. R-NH2/TBTU/DIEA/DCM).
Scheme 15.
Figure imgf000057_0001
The following is an exemplary procedure for the preparation of a compound of the invention.
Synthesis of 2-chloro-4-nitrobenzocarboxaldehyde (54) and N-(3-chloro-4-(2-(3,4- difluorobenzylamino)-9-((R)-piperidin-3-ylmethyl)-9H-purin-8-yl)phenyl)acetamide 2,2,2- trifluoroacetate (547) One possible process for the synthesis of compound 547 (Scheme 16) is detailed in the following description. Compound 13' is prepared in accordance with syntheses described before (Scheme 3 and corresponding procedures).
Scheme 16.
Figure imgf000058_0001
Compound 53
Starting with acid chloride 51: 2-chloro-4-nitrobenzoylchloride 51 (6.22 g, 28.3 mmol, 1.0 equiv.) can be reduced by using NaBH4 (1.1 g, 28.3 mmol, 1.0 equiv.) in a DME (30 mL) / MeOH (15 mL) mixture. After workup, product 53 was obtained in 54% yield (2.89 g).
Starting with acid 52: a solution of 2-chloro-4-nitrobenzoic acid (15.95 g, 79 mmol, 1.0 equiv.) in THF (200 mL) was cooled to 0 °C. BH3 (118.7 mL, 118.7 mmol, 1 M solution in THF, 1.5 equiv.) was added dropwise. Reaction mixture was allowed to warm to room temperature and stirred for 16 h. A sat'd solution OfK2CO3 in water was added dropwise untill gas evolution stopped. After precipitation of a white solid, the r.m. was filtered and washed with EtOAc. Filtrate and washings were combined and concentrated in vacuo. The product was redissolved in EtOAc, washed with IN HCl (2x), sat'd NaHCO3 and brine and dried on Na2SO4. After filtration and concentration in vacuo, compound 53 was obtained as a yellowish solid in 97% yield (14.45 g)-
Compound 54
A solution of oxalyl chloride (8.6 ml, 100 mmol, 1.3 equiv.) in DCM (250 ml) was cooled to -70 °C. A solution of DMSO (8.9 ml, 125 mmol, 1.6 equiv.) in DCM (50 ml) was added slowly, maintaining temperature below -70 °C. The mixture was stirred for 15 minutes. Compound 52 (14.45 g, 77 mmol, 1.0 equiv.) was dissolved in DCM (150 ml) and the solution was added dropwise to the mixture. After addition, the mixture was stirred at -70 °C for 45 minutes. Et3N (54 mL, 385 mmol, 5.0 equiv.) was added to the mixture, then the mixture was allowed to warm to the room temperature and stirred overnight. The mixture was diluted with DCM (500 mL) and washed with sat'd NH4Cl (2x), water and brine. After drying on Na2SO4, filtration and concentration in vacuo, compound 54 was obtained as a solid in a quantitative yield (14.29 g).
Compound 55 To a solution of compound 13' (13 g, 28.9 mmol, 1.0 equiv.) in DMA (200 ml) was added AcOH (30 ml) and aldehyde 54 (8.7 g, 46.8 mmol, 1.6 equiv.). The reaction mixture was heated to 140 °C overnight with air bubbling through the reaction mixture. After completion, rm was cooled to rt, diluted with EtOAc and washed with water (3x) and brine. After drying on Na2SO4, filtration and concentration in vacuo, the crude product was purified by column chromatography (5% MeOH/95% DCM). Compound 55 was obtained in a 45% yield (8.13 g).
Compound 56
To a solution of compound 55 (8.13 g, 13.24 mmol) in MeOH (100 ml) and THF (100 ml) was added Raney Ni under N2-atmosphere. The rm was stirred under H2-atmosphere for 3 h. The mixture was filtered over celite and concentrated in vacuo. The crude product was redissolved in DCM, some impurities remaining insoluble. After filtration, the filtrate was purified using column chromatography (5% MeOH/95% DCM). The product was purified again by dissolving in DCM and reprecipitatation by heptane. The supernatant was separated and the product was dried under vacuum. Compound 56 was obtained in a 43% yield (3.3 g).
Compound 57
To a solution of AcOH (4.94 μl, 0.086 mmol, 1.0 equiv.) in DCM (2 ml) was added TBTU (41.2 mg, 0.128 mmol, 1.5 equiv.) and DIEA (45 μl, 0.257 mmol, 3.0 equiv.). Rm was stirred at rt for
10 minutes. To this mixture was added a solution of compound 56 (50 mg, 0.086 mmol, 1.0 equiv.) in DCM (1 ml). The rm was sitrred at r.t. overnight.
Extra TBTU and acetic acid (2 equiv.) were needed to complete the reaction over 72 h.
The r.m. was poured out in sat'd NaHCO3 and extracted with EtOAc (2x). After washing with brine, drying on Na2SO4, filtration and concentration in vacuo, the crude product was purified by column chromatography (DCM : MeOH 9 : 1). Compound 57 was obtained in a 100% yield (53 mg). N-(3-chloro-4-(2-(3,4-difluorobenzylamino)-9-((R)-piperidin-3-ylmethyl)-9H-purin-8- yl)phenyl)acetamide 2,2,2-trifluoroacetate (547)
To a solution of compound 57 (53 mg, 0.086 mmol) in DCM (1 ml) was added TFA (0.5 ml).
Rm was stirred at rt for 30 minutes. The reaction mixtured was concentrated in vacuo and the crude product was purified by prep-HPLC (0 - 50% ACN with TFA).
Product fractions were concentrated and lyophilized to obtain the TFA-salt of compound 547 in a
40% yield (22 mg).
TFA-salt: 1H NMR (400 MHz, DMSO-D6), ppm: 10.42 (s, 1H), 8.72 (s, 1H), 8.52 (br d, 1H),
8.16 (m, 1H), 8.03 (m, 1H), 7.92 (br s, 1H), 7.63 (d, 1H), 7.57 (d, 1H), 7.43 (m, 1H), 7.37 (m,
1H), 7.24 (br s, 1H), 4.53 (m, 2H), 3.91 (m, 1H), 3.80 (m, 1H), 3.11 (br d, 1H), 2.94 (br d, 1H),
2.65 (m, 1H), 2.44 (m, 1H), 2.12 (s, 3H), 2.03 (br s, 1H), 1.62 (m, 1H), 1.36 (m, 2H), 0.96 (m,
1H).
5. Another possible synthetic route towards compounds of the invention in which R3 is an ortho,ortho-dic\ύoroary\ with an amide at the pαrα -position is described in the scheme below
(Scheme 17.).
After ringclosing reaction to the purines, the Cbz-N-group can be deprotected by procedures well known in the art (e.g. Pd/C/H2). The primary amine can be functionalized to e.g. a carbamate or reversed amide by procedures well known in the art (e.g. R-NH2/TBTU/DIEA/DCM).
Scheme 17.
Figure imgf000062_0001
The following is an exemplary procedure for the preparation of a compound of the invention.
Synthesis of benzyl-3,5-dichloro-4-formylphenylcarbamate (65) and (R)-N-0, 5-dichloro-4-(2- (3,4-difluorobenzylamino)-9-(piperidin-3-ylmethyl)-9H-purin-8-yl)phenyl)acetamide 2,2,2- trifluoroacetate (553)
One possible process for the synthesis of compound 553 (Scheme 18) is detailed in the following description. Compound 13' is prepared in accordance with syntheses described before (Scheme 3 and corresponding procedures). Scheme 18.
Figure imgf000063_0001
Compound 59
To a solution of compound 58 (86.7 g, 0.49 mol, 1.0 equiv.) in THF (2 L) at 0 °C was added CbzCI (70 ml, 0.49 mol, 1.0 equiv.) dropwise and stirred mechanically. The mixture was stirred overnight at room temperature. The mixture was filtered, stirred with EtO Ac/heptane and filtered again. The mother liquor was stirred with 200 ml of triethylamine for 3 h. The filtered solid was also added to the mixture and it was stirred overnight. The mixture was concentrated, NaHC03- sat'd was added, extraction with EtOAc and concentration in vacuo. To lose the disubstituted (bis-CBz) byproduct, the mixture was redissolved in THF and 4N NaOH (200 rnL) was added. The mixture was stirred at 50°C overnight and cooled to rt. The mixture was acidified to pH=3 and extracted with EtOAc (3x). The combined organic layers were washed with sat'd NaHCO3 and brine and dried over Na2SO4. After filtration and concentration in vacuo, the solid was dissolved in DCM and precipitated with heptane to afford the CBz-protected aminophenol 59 in 52% yield (80 g).
Compound 60
To a solution of compound 59 (80 g, 256 mmol, 1.0 equiv.) in DCM (1 L) was added 2,6-lutidine (60.5 g, 564 mmol, 2.2 equiv.). The mixture was cooled to -78°C. Triflic anhydride (86.8 g, 307 mmol, 1.2 equiv.) was added dropwise while keeping the temperature below -75°C. The reaction mixture was stirred overnight at room temperature. After completion, the reaction mixture was diluted with TBME and washed with water (3x), brine, dried on Na2SO4, filtered and concentrated in vacuo.
The crude material was purified by column chromatography (heptane: EtOAc 9:1) to yield 88% (91.5 g) of compound 60.
Compound 63
A mixture of 1-heptyne 62 (75 g, 777 mmol, 2.0 equiv.) and pinacolborane 61 (49.7 g, 388 mmol, 1.0 equiv.) was stirred overnight at 70°C. Rm was concentrated in vacuo (evaporation of unreacted 1-heptyne and pinacolborane) to yield compound 63 in 43 % yield. Unreacted compounds 61 and 62 were stirred again for two days at 80°C. After concentration in vacuo compound 63 was obtained. Combining both batches gave an overall yield of 73% (63.6 g).
Compound 64
Compound 60 (54 g, 122 mmol, 1.0 equiv.) and compound 63 (30 g, 134 mmol, 1.1 equiv.) were dissolved in DME. A solution OfNa2CO3 (39 g, 366 mmol, 3.0 equiv.) in water (70 ml) was added and the mixture was degassed (3x) and put under N2-atmosphere. Pd(PPh3 )4 (2.6 g, 2.5 mmol, 0.02 equiv.) was added. The reaction was stirred for 72 h at 70°C. After completion, the mixture was filtered over C elite and washed with water and EtOAc. The filtrate was extracted with EtOAc (3x). Combined organic layers were washed with brine, dried on Na2S04,filtered and concentrated in vαcwo.After purification by column chromatography (heptane: EtOAc 9:1) compound 64 was obtained in 52% yield (25 g).
Benzyl- 3, 5-dichloro-4-formylphenylcarbamate (65)
A solution of compound 64 (9.4 g, 24 mmol) in DCM (200 ml) at -78 °C was bubbled through with ozone until a blue color appeared. This color maintained for 5 minutes. The rm was flushed with nitrogen for approximately 20 minutes. DMS (7.4 g, 120 mmol, 5.0 equiv.) was added and the rm was stirred o.n. at rt.
Water was added and the organic layer was extracted with water (3x). The water layers were collected and extracted with EtOAc/THF (3x). Combined organic layers were washed with brine, dried on Na2S04,filtered and concentrated in vacuo.
The product was crystallized by EtO Ac/heptane. After filtration and drying, compound 65 was obtained in 62% yield (4.8 g).
Compound 69
To a solution of compound 13' (1.70 g, 3.8 mmol) in DMA (20 ml) was added compound 65 (2.46 g, 7.60 mmol, 2.0 equiv.) and AcOH (3.26 ml, 57.0 mmol, 15 equiv.). Rm was stirred o.n. at 105 °C in a open flask. After completion, the reaction mixture was cooled to rt and extracted with EtOAc (2x). After washing with water(2x) and brine, the crude product was dried on Na2SO4 and concentrated in vacuo. The crude product was purified by column chromatography (100 % heptaan to 100 % EtOAc). Product fractions were concentrated in vacuo to obtain compound 69 in 77 % yield (2.20 g). Compound 70
Compound 69 (2.09 g, 2.78 mmol, 1.0 equiv.) was dissolved in methanol (100 ml). Pd/C (0.164 g, 0.139 mmol, 0.05 equiv.) was added. The reaction mixture was stirred under H2-HoW for 4.5 h. Pd/C was filtered off over Celite, Celite was washed with EtOAc. The filtrate was concentrated in vacuo. After purification by column chromatography (heptaan: EtOAc 4:1 to pure EtOAc) compound 70 was obtained in 55 % yield (958 mg).
Compound 71
To a solution of acetic acid (5.09 μl, 0.089 mmol, 1.1 equiv.) in DCM (2 ml) was added DIEA (56.3 μl, 0.323 mmol, 4.0 equiv.) and TBTU (36.3 mg, 0.113 mmol, 1.4 equiv.). Rm was stirred at rt for 10 min. A solution of compoundxxx in DCM (ImI) was added to this mixtured. Rm was stirred at rt for 4 h. Extra acetic acid, TBTU, DIEA and a few drops of DMF were added. Rm was stirred at rt for 72 h. After completion, water was added to the r.m. The r.m. was extracted with DCM, washed with brine and concentrated in vacuo to obtain compound 71.
(R)-N- (3, 5-dichloro-4- (2-(3, 4-difluorobenzylamino)-9-(piperidin-3-ylmethyl)-9H-purin-8- yl)phenyl)acetamide 2,2,2-trifluoroacetate (553)
To a solution of compound xxx in DCM (1 ml) was added TFA (0.2 ml). R.m. was stirred at rt for 30 minutes. After concentration in vacuo, the crude product was purified by prep-HPLC (0- 70% ACN, with TFA). Productfractions were concentrated in vacuo, lyophilization in ACN/H2O obtained compound 553 as the TFA-salt in 92% yield (50 mg).
TFA-salt: 1H NMR (400 MHz, DMSO-D6), ppm: 10.60 (s, 1H), 8.62 (br d, 1H), 8.27 (br d, 1H), 7.96 (br s, 1H), 7.93 (s, 1H), 7.88 (s, 1H), 7.44 (m, 1H), 7.38 (m, 1H), 7.25 (m, 1H), 4.53 (m, 2H), 3.86 (m, 1H), 3.72 (m, 1H), 3.15 (br d, 1H), 3.08 (br d, 1H), 2.67 (m, 1H), 2.57 (m, 1H), 2.14 (s, 3H), 2.10 (m, 1H), 1.63 (br d, 1H), 1.38 (m, 2H), 1.01 (m, 1H). 6. Another possible route for preparing purine analogs of the invention in which R2 is a linear (3C-5C) substituted amine is shown in Scheme 19.
The most reactive chloride in the 2-position of pyrimidine 1 is first displaced by TBDMSO(C3- C5)NH2 to yield compound 72. The chloride at the 4-position is then substituted with NH2-RΛ Reduction of the nitro group in 73 to an amine (74) using reagents well known in the art (e.g. Na2S2θ4/NH4θH/H2O/dioxane, Pd(C)/H2/MeOH), followed by cyclization with an aryl aldehyde gives TBDMS-deprotected purine 75. Conversion to the mesylate 76 and subsequent reaction with secondary amines can lead to purines 77.
Scheme 19
Figure imgf000067_0001
R"— CHO
R"VR""
Figure imgf000067_0002
[0093] PKC-theta IMAP Assay I
[0094] The activity of the compounds described in the present invention may be determined by the following procedure. This procedure describes a kinase assay that measures the phosphorylation of a fluorescently-labeled peptide by full-length human recombinant active PKCΘ via fluorescent polarization using commercially available IMAP reagents. [0095] The PKCΘ used is made from full-length, human cDNA (accession number
LO 1087) with an encoded His-6 sequence at the C-terminus. PKCΘ is expressed using the baculovirus expression system. The protein is purified with Ni-NTA affinity chromatography yielding a protein with 91% purity.
[0096] The substrate for this assay is a fluorescently-labeled peptide having the sequence
LHQRRGSIKQAKVHHVK (FITC)-NH2. The stock solution of the peptide is 2 mM in water.
[0097] The IMAP reagents come from the IMAP Assay Bulk Kit, product #R8063 or
#R8125 (Molecular Devices, Sunnyvale, CA). The kit materials include a 5X IMAP Binding Buffer and the IMAP Binding Reagent. The Binding Solution is prepared as a 1 :400 dilution of IMAP Binding Reagent into the IX IMAP Binding Buffer.
[0098] The substrate/ATP buffer for this assay consists of 20 mM HEPES, pH 7.4 with 5 mM MgCl2, and 0.01% Tween-20. Additionally, the buffer contains 100 nM substrate, 20 μM ATP, and 2 mM DTT which are added fresh just prior to use. The kinase buffer containing the PKCΘ consists of 20 mM HEPES, pH 7.4 with 0.01% Tween-20. This buffer also contains .2 ng/μL PKCΘ and 2 mM DTT which are added fresh just prior to use.
[0099] The plates used are Corning 3710 (Corning Incorporated, Corning, NY). These are non-treated black polystyrene, 384-well with flat-bottoms. The serial dilutions are performed Nunc V-bottom 96-well plates.
[00100] The assay procedure starts the preparation of stock solutions of compounds at 10 mM in 100% DMSO. The stock solutions and the control compound are serially diluted 1 :3.16 a total of 11 times into DMSO (37 μL of compound into 80 μL of DMSO). After the serial dilution has been completed, a further dilution is performed by taking 4 μL compound and adding to 196 μL substrate/ ATP Buffer. Then, 10 μL aliquots of the compounds are transferred to the Costar 3710 plate. The kinase reaction is initiated by the addition of 10 μL PKCΘ. This reaction is allowed to incubate for 1 hour at ambient temperature. The reaction is then quenched by the addition of 60 μL of Binding Solution. The plate is incubated for an additional 30 minutes at ambient temperature. The assay is measured using an Acquest™ Ultra-HTS Assay Detection System (Molecular Devices) in fluorescence polarization mode using 485 nm excitation and 530 nm emission.
PKC-theta IMAP Assay II
[00101] The activity of the compounds of the present invention is determined by the following procedure. This procedure describes a kinase assay that measures the phosphorylation of a fluorescently-labeled peptide by full-length human recombinant active PKCΘ via fluorescent polarization using commercially available IMAP reagents.
[00102] The PKCΘ used is made from full-length, human cDNA (accession number
LO 1087) with an encoded His-6 sequence at the C-terminus. PKCΘ is expressed using the baculovirus expression system. The protein is purified with Ni-NTA affinity chromatography yielding a protein with -70% purity.
[00103] The substrate for this assay is a fluorescently-labeled peptide having the sequence
LHQRRGSIKQAKVHHVK (FITC)-NH2. The stock solution of the peptide is 0.06M in MiIIiQ water.
[00104] The IMAP reagents originate from the IMAP buffer kit with Progressive Binding
System, product #R8127 (Molecular Devices, Sunnyvale, CA). The Binding Solution is prepared as a 1 :400 dilution of IMAP Progressive Binding Reagent into the IX buffer A IMAP Binding Buffer.
[00105] The kinase reaction buffer for this assay consists of 10 mM Tris-HCl, 10 mM
MgC12, 0.01% Tween-20, 0.05% NaN3, pH 7.2, and 1 mM DTT (freshly added prior to use).
[00106] The plates used are Black 384-F Optiplates (product # 6007279, Packard).
[00107] The assay procedure starts with the preparation of serial dilutions of the compounds stored in 100% DMSO. The compounds are 10 times serially diluted 1 :3.16, resulting in a final compound concentration range from 10 μM to 0.316 nM.. All reagent solutions are prepared in kinase reaction buffer.
To 5 μl compound solution (4% DMSO), 5 μl of an ATP solution of 40 μM is added to the well. Subsequently, 5 μl of a 200 nM substrate solution is added. The kinase reaction is initiated by the addition of 5μl PKCΘ solution of 40 ng/ml. This reaction is allowed to incubate for 1 hour at ambient temperature. The reaction was stopped by adding 40 μl of IMAP Progressive Binding Solution. The plate is incubated for an additional 60 minutes at ambient temperature in the dark. Fluorescence polarization is measured using an Envision Multilabel reader (Perkin Elmer) in fluorescence polarization mode using 485 nm excitation and 530 nm emission.
[00108] Table 1 illustrates several examples of the compounds of the invention. These compounds are synthesized using one of the suitable procedures described above. The molecular weight of the compounds is confirmed by mass spectroscopy (m/z). The compounds of Table 1 are tested using one of the above-described PKCΘ IMAP assays. Entries in the 100, 200 , 300 and 400 series are tested using PKC-theta IMAP assay 1 and Entries in the 500, 600 and 700 are tested using PKC-theta IMAP assay II.
[00109] All compounds in Table 1 below exhibit PKCΘ IMAP assay IC50 values less than 10 μM. Entries in the 100 and 500 series exhibit IC50 values less than 100 nM; entries in the 200, 300 and 600 series exhibit IC50 values less than 1 μM; and entries in the 400 and 700 series exhibit IC50 values less than 10 μM.
Table 1
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
431 432
Figure imgf000113_0002
433 434
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
473 474
Figure imgf000123_0002
475 476
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
Figure imgf000127_0001
Figure imgf000128_0001
Figure imgf000129_0001
Figure imgf000130_0001
Figure imgf000131_0001
Figure imgf000132_0001
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Figure imgf000136_0001
Figure imgf000137_0001
Figure imgf000138_0001
Figure imgf000139_0001
Figure imgf000140_0001
Figure imgf000141_0001
Figure imgf000142_0001
Figure imgf000143_0001
Figure imgf000144_0001
Figure imgf000145_0001
Figure imgf000146_0001
[00110] The data presented in Table 1 demonstrates utility of the compounds of the invention in inhibition of PKC θ. Therefore, the compounds of the invention are useful in treatment of T-
Page l45 of 173 cell mediated diseases including autoimmune disease such as rheumatoid arthritis and lupus erythematosus, and inflammatory diseases such as asthma and inflammatory bowel disease. Additionaly, the compounds of the invention are useful in treatment of gastrointestinal cancer and diabetes.
[00111] Selectivity for inhibition of PKC#by the compounds of the invention was tested and results are shown in Table 2. The data in Table 2 shows obtained values for PKC θ isoform selectivity by showing Kz Pan Vera (PV) potencies for PKC θ, PKC delta and PKC alpha. For Kz Pan Vera (PV) of PKC θ, entries identified with "A" had values below 100 nM; entries identified with "B" had values below 1 μM; and entries identified with "C" had values below 10 μM. For Kz Pan Vera (PV) of PKC delta and PKC alpha, entries identified with "1" had values above 250 nM; entries identified with "2" had values above 1 μM; entries identified with "3" had values above 10 μM.
[00112] Table 2 also shows selectivity of the compounds of the invention by showing their IC50 values for SGK kinase. Entries identified with "1" had values above 250 nM; entries identified with "2" had values above 1 μM; entries identified with "3" had values above 10 μM.
Table 2.
Figure imgf000147_0001
Figure imgf000148_0001
Figure imgf000149_0001
Figure imgf000150_0001
[00113] The compounds of the invention were also tested in vivo. Table 3 below demonstrates results of anti-CD3 induced interleukin-2 (IL-2) production in mice, which was performed following protocols disclosed in Goldberg et al. (2003), J. Med. Chem. 46, 1337- 1349.
Table 3.
Figure imgf000150_0002
[00114] IL-2 is a T cell-derived lymphokine that modulates immunological effects on many cells of the immune system, including cytotoxic T cells, natural killer cells, activated B cells and lymphokine-activated cells. It is a potent T cell mitogen that is required for the T cell proliferation, promoting their progression from Gl to S phase of the cell cycle. It is a growth factor for all subpopulations of T lymphocytes, as well as stimulating the growth of NK cells. It also acts as a growth factor to B cells and stimulates antibody synthesis. [00115] Due to its effects on both T and B cells, IL-2 is a major central regulator of immune responses. It plays a role in anti-inflammatory reactions, tumor surveillance, and hematopoiesis. It also affects the production of other cytokines, inducing IL-I, TNF-α and TNF-β secretion, as well as stimulating the synthesis of IFN-γ in peripheral leukocytes. IL-2, although useful in the immune response, also causes a variety of problems. IL-2 damages the blood-brain barrier and the endothelium of brain vessels. These effects may be the underlying causes of neuropsychiatric side effects observed under IL-2 therapy, e.g. fatigue, disorientation and depression. It also alters the electrophysiological behavior of neurons.
[00116] T cells that are unable to produce IL-2 become inactive (anergic). This renders them potentially inert to any antigenic stimulation they might receive in the future. As a result, agents which inhibit IL-2 production may be used for immunosupression or to treat or prevent inflammation and immune disorders. This approach has been clinically validated with immunosuppressive drugs such as cyclosporin, FK506, and RS61443.
[00117] The data presented in Tables 1-3 demonstrates utility of the compounds of the invention in inhibition of PKC θ and their utility for treatment of T-cell mediated diseases including autoimmune diseases such as rheumatoid arthritis, lupus erythematosus, and multiple sclerosis, inflammatory diseases such as asthma and inflammatory bowel disease, transplant rejection, gastrointestinal cancer, and diabetes.
[00118] Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisometric forms which may be defined in terms of absolute stereochemistry as (R)- or (S)-. The present invention is meant to include all such possible diastereomers as well as their racemic and optically pure forms. Optically active (R)- and (S)- isomers may be prepared using homo-chiral synthons or homo- chiral reagents, or optically resolved using conventional techniques. When the compounds described herein contain olefmic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended to include both (E)- and (Z)- geometric isomers. Likewise, all tautomeric forms are intended to be included. [00119] The graphic representations of racemic, ambiscalemic and scalemic or enantiomerically pure compounds used herein are taken from Maehr J. Chem. Ed. 62, 114-120 (1985): solid and broken wedges are used to denote the absolute configuration of a chiral element; wavy lines indicate disavowal of any stereochemical implication which the bond it represents could generate; solid and broken bold lines are geometric descriptors indicating the relative configuration shown but denoting racemic character; and wedge outlines and dotted or broken lines denote enantiomerically pure compounds of indeterminate absolute configuration. Thus, among the structures below, those having open wedges are intended to encompass both of the pure enantiomers of that pair, those having solid wedges are intended to encompass the single, pure enantiomer having the absolute stereochemistry shown.
[00120] The present invention includes compounds of formula (I) in the form of salts. Suitable salts include those formed with both organic and inorganic acids. Such salts will normally be pharmaceutically acceptable, although non-pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question. The term "pharmaceutically acceptable salt" refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids and bases and organic acids and bases. When the compounds of the present invention are basic, salts may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids. Suitable pharmaceutically acceptable acid addition salts for the compounds of the present invention include acetic, benzenesulfonic (besylate), benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric acid, p-toluenesulfonic, and the like. When the compounds contain an acidic side chain, suitable pharmaceutically acceptable base addition salts for the compounds of the present invention include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. [00121] While it may be possible for the compounds of formula (I) or their salts and solvates to be administered as the raw chemical, it is preferable to present them as a pharmaceutical composition. According to a further aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically carriers thereof and optionally one or more other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
[00122] The formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), rectal and topical (including dermal, buccal, sublingual and intraocular) administration. The most suitable route may depend upon the condition and disorder of the recipient. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof ("active ingredient") with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
[00123] Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.
[00124] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide sustained, delayed or controlled release of the active ingredient therein.
[00125] Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient. Formulations for parenteral administration also include aqueous and non-aqueous sterile suspensions, which may include suspending agents and thickening agents. The formulations may be presented in unit- dose of multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of a sterile liquid carrier, for example saline, phosphate-buffered saline (PBS) or the like, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
[00126] Formulations for rectal administration may be presented as a suppository with the usual carriers, such as cocoa butter or polyethylene glycol.
[00127] Formulations for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active ingredient in a flavored basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.
[00128] Preferred unit dosage formulations are those containing an effective dose, or an appropriate fraction thereof, of the active ingredient.
[00129] The pharmaceutical compositions will usually include a "pharmaceutically acceptable inert carrier" and this expression is intended to include one or more inert excipients, which include starches, polyols, granulating agents, microcrystalline cellulose, diluents, lubricants, binders, disintegrating agents, and the like. If desired, tablet dosages of the disclosed compositions may be coated by standard aqueous or nonaqueous techniques. "Pharmaceutically acceptable carrier" also encompasses controlled release means. Compositions of the present invention may also optionally include other therapeutic ingredients, anti-caking agents, preservatives, sweetening agents, colorants, flavors, desiccants, plasticizers, dyes, and the like.
[00130] The compounds of formula (I) are preferably administered orally or by injection (intravenous or subcutaneous). The precise amount of compound administered to a patient will be the responsibility of the attendant physician. However, the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity. Also, the route of administration may vary depending on the condition and its severity.
[00131] The contents of each of the references cited herein, including the contents of the references cited within the primary references, are herein incorporated by reference in their entirety.

Claims

1. A compound, or salt thereof, represented by Formula I,
(I)
wherein:
R1 is chosen from C1 -C
Figure imgf000156_0001
4 alkyl, carbocyclyl, substituted carbocyclyl, and R4 wherein
R4 is chosen from cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, wherein R4 may be substituted, with a proviso that when R4 is a heteroaryl, R4 is not bonded via a heteroatom to the methylene carbon bearing the Z group; and
Z is chosen from -H and C1-C4 alkyl; R2 is chosen from -(C2-C7 alkyl)-NR5R6, -(C0-C4 alkyl)-R7-R8, and
-(C0-C4 alkyl)-C(0)-(Co-C4 alkyl)-R7-R8, wherein
R7 is cyclyl, with a proviso that when R7 is a heterocyclyl, a purine nitrogen of Formula I bonded to R2 is not bonded to a heteroatom of R7 directly or via a methylene group;
R8 is chosen from -(C0-C4 alkyl)-NR5R6, and
-C(O)-(C0-C4 alkyl)-NR5R6, and, when R7 is nitrogenous heterocyclyl,
R8 may additionally be -H, with a proviso that when R7 is a heterocyclyl and R8 is
-(C0-C4 alkyl)— NR5R6, a heteroatom of R7 is not bonded to
-NR5R6 directly or via a methylene group; R5 and R6 are independently chosen from -H and C1 -C4 alkyl; and R3 is chosen from C1-C6 alkyl, aryl, substituted aryl, arylalkyl, substituted arylalakyl, heteroaryl and substituted heteroaryl; with a proviso that when R3 is phenyl and R2 is piperidin-4-yl-ethyl, R1 is not cyclopropyl.
2. A compound, or salt thereof, according to claim 1, wherein:
R1 is chosen from C1-C4 alkyl, phenyl optionally substituted with one or two substituents independently chosen from halogen, OCH3, -CF3, -OCF3 and C1-C4 alkyl
Figure imgf000157_0001
wherein
R4 is -(C0-C4 alkyl)-R9, wherein
R9 is chosen from cycloalkyl, aryl, and heteroaryl, wherein R9 is optionally substituted at one or two atoms with substituents independently chosen from halogen, -OH, -OCH3, -CF3, -OCF3, CN, C1-C4 alkyl, and pyridinyl; and Z is chosen from -H and C1-C4 alkyl.
3. A compound, or salt thereof, according to claim 1, wherein:
R2 is chosen from -(C2-C7 alkyl)-NR5R6, -(C0-C4 alkyl)-R7-R8, and -(C0-C4 alkyl)-C(O)-(C0-C4 alkyl)-R7-R8, wherein R7 is chosen from alicyclyl, nitrogenous alicyclyl, aryl, and nitrogenous heteroaryl;
R8 is chosen from -H, -(C0-C4 alkyl)-NR5R6, and -C(O)-(C0-C4 alkyl)-NR5R6; and R , 5 and R are independently chosen from -H and -(C1-C4 alkyl).
4. A compound, or salt thereof, according to claim 1, wherein:
R3 is chosen from C1-C6 alkyl, aryl, aryl substituted with R10, R11 and R12, wherein
R10, R11 and R12 are independently chosen from -H, halogen, -OCH3, -CF3, -OCF3, -CN, C1-C4 alkyl, -NR13R14, -S(O)1nCH3, -CONHR22, -NHCOR23, OR24 and -NHS(O)1nR25; wherein
R13 and R14 are independently chosen from -H and C1-C4 alkyl; R22, R23 and R24 are one or two substituents independently chosen from -H, C1-C4 alkyl, C1-C6 cycloalkyl, aryl, -(CH2)nNR26R27 and -(CH2)nOR28 said C1-C4 alkyl and C1-C6 cycloalkyl being optionally substituted with one or more halogens;
R25 is C1-C4 alkyl;
R26 and R27 are independently chosen from H and C1-C4 alkyl or
R26 and R27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O;
R28 is chosen from H and C1-C4 alkyl; m is O , 1 or 2 and n is 1, 2 or 3.
5. A compound, or salt thereof, according to claim 1, wherein:
R1 is chosen from C1-C4 alkyl, phenyl optionally substituted with one or two substituents independently chosen from halogen, OCH3, -CF3, -OCF3 and C1-C4 alkyl
Figure imgf000158_0001
wherein
Figure imgf000159_0001
wherein
R15 and R16 are independently chosen from -H, halogen, -OH, -OCH3, - CF3, -OCF3, -CN, C1-C4 alkyl, and pyridinyl; R17 is chosen from O and S; R18 is chosen from CH and N; R19 and R20 are independently chosen from -H, halogen, -OCH3, -CF3, -OCF3, -CN, C1-C4 alkyl, and pyridinyl; and Z is chosen from -H and C1-C4 alkyl.
6. A compound, or salt thereof, according to claim 1, wherein:
R2 is chosen from -(C2-C7 alkyl)-NR5R6, -(C0-C4 alkyl)-R7-R8, and -(C0-C4 alkyl)-C(0)-(Co-C4 alkyl)-R7-R8, wherein R7 is chosen from cyclohexyl, phenyl, piperidinyl, pyrrolidinyl, morpholinyl, and piperazinyl; R8 is chosen from -H, -(C0-C4 alkyl)-NR5R6, and
-C(O)-(C0-C4 alkyl)-NR5R6; and R5 and R6 are independently chosen from -H and -(C1-C4 alkyl).
7. A compound, or salt thereof, according to claim 1, wherein:
R2 is other than
Figure imgf000159_0002
8. A compound, or salt thereof, according to claim 1, wherein:
R3 is chosen from C1-C6 alkyl,
Figure imgf000160_0001
, and , wherein
R10, R11 and R12 are independently chosen from -H, halogen, -OCH3, -CF3, -OCF3, -CN, C1-C4 alkyl, -NR13R14, -S(O)1nCH3, -CONHR22, -NHCOR23, OR24 and -NHS(O)1nR25; wherein
R13 and R14 are independently chosen from -H and C1-C4 alkyl; R22, R23 and R24 are one or two substituents independently chosen from -H, C1-C4 alkyl, C1-C6 cycloalkyl, aryl, -(CH2)nNR26R27 and -(CH2)nOR28 said C1-C4 alkyl and C1-C6 cycloalkyl being optionally substituted with one or more halogens;
R25 is C1-C4 alkyl;
R26 and R27 are independently chosen from H and C1-C4 alkyl or
R26 and R27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O;
R28 is chosen from H and C1-C4 alkyl; m is O , 1 or 2 and n is 1, 2 or 3.
9. A pharmaceutical composition comprising a compound, or salt thereof, according to claim 1 , and a pharmaceutically acceptable carrier.
10. A compound, or salt thereof, represented by Formula I,
(I)
Figure imgf000161_0001
wherein:
R1 is chosen from straight or branched C1-C4 alkyl, phenyl optionally substituted with one or two substituents independently chosen from halogen, OCH3, -CF3, -OCF3 and
C1-C4 alkyl
Figure imgf000161_0002
wherein
R4 is -(C0-C4 alkyl)-R9, wherein R9 is chosen from cycloalkyl, aryl, and heteroaryl, wherein R9 is optionally substituted at one or two atoms with substituents independently chosen from halogen, -OH, -OCH3, - CF3, -OCF3, -CN, C1-C4 alkyl, and pyridinyl, with a proviso that when R9 is a heteroaryl, R9 is not bonded via a heteroatom to the methylene carbon bearing the Z group; and Z is chosen from -H and C1-C4 alkyl;
R2 is chosen from -(C2-C7 alkyl)-NR5R6, -(C0-C4 alkyl)-R7-R8, and -(C0-C4 alkyl)-C(O)-(C0-C4 alkyl)-R7-R8, wherein
R7 is chosen from alicyclyl, nitrogenous alicyclyl, aryl, and nitrogenous heteroaryl, with a proviso that when R7 is a nitrogenous alicyclyl or a nitrogenous heteroaryl, a purine nitrogen of Formula I bonded to R2 is not bonded directly or via a methylene group to a nitrogen of R7; R8 is chosen from, -(C0-C4 alkyl)-NR5R6, and -C(O)-(C0-C4 alkyl)— NR5R6, and, when R7 is nitrogenous alicyclyl or nitrogenous heteroaryl, R8 may additionally be
-H, with a proviso that when R7 is a nitrogenous alicyclyl or a nitrogenous heteroaryl and R8 is -(Co-C4 alkyl)— NR5R6, a nitrogen of R7 is not bonded directly or via a methylene group to -NR5R6; and R5 and R6 are independently chosen from -H and -(C1-C4 alkyl); R3 is chosen from C1-C6 alkyl, aryl, aryl substituted with R10, R11 and R12, wherein
R10, R11 and R12 are independently chosen from -H, halogen, -OCH3, -CF3, -OCF3, -CN, C1-C4 alkyl, -NR13R14, -S(O)1nCH3, -CONHR22, -NHCOR23, - OR24 and -NHS(O)1nR25; wherein
R13 and R14 are independently chosen from -H and C1-C4 alkyl; R22, R23 and R24 are one or two substituents independently chosen from -H, C1-C4 alkyl, C1-C6 cycloalkyl, aryl, -(CH2)nNR26R27 and -(CH2)nOR28 said C1-C4 alkyl and C1-C6 cycloalkyl being optionally substituted with one or more halogens; R25 is C1-C4 alkyl;
R26 and R27 are independently chosen from H and C1-C4 alkyl or R26 and R27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O; R28 is chosen from H and C1-C4 alkyl; m is O , 1 or 2 and n is 1, 2 or 3.
11. A compound, or salt thereof, according to claim 10, wherein: R1 is chosen from C1 -C4 alkyl, phenyl optionally substituted with one or two substituents independently chosen from halogen, OCH3, -CF3, -OCF3 and C1-C4 alkyl
Figure imgf000163_0001
wherein
R4 is chosen from
Figure imgf000163_0002
Figure imgf000163_0003
wherein
R15 and R16 are independently chosen from -H, halogen, OH, -OCH3, -CF3, -OCF3, -CN, C1-C4 alkyl, and pyridinyl; R17 is chosen from O and S; R18 is chosen from CH and N;
R19 and R20 are independently chosen from -H, halogen, -OCH3, -CF3, - OCF3, -CN, C1-C4 alkyl, and pyridinyl; and Z is chosen from -H and C1-C4 alkyl.
12. A compound, or salt thereof, according to claim 10, wherein:
R2 is chosen from -(C2-C7 alkyl)-NR5R6, -(C0-C4 alkyl)-R7-R8, and -(C0-C4 alkyl)-C(0)-(Co-C4 alkyl)-R7-R8, wherein R7 is chosen from cyclohexyl, phenyl, piperidinyl, pyrrolidinyl, morpholinyl, and piperazinyl; R8 is chosen from -H, -(C0-C4 alkyl)-NR5R6, and
-C(O)-(C0-C4 alkyl)-NR5R6; and R5 and R6 are independently chosen from -H and -(C1-C4 alkyl).
13. A compound, or salt thereof, according to claim 10, wherein:
R is other than
Figure imgf000164_0001
14. A compound, or salt thereof, according to claim 10, wherein:
R3 is chosen from C1-C6 alkyl,
Figure imgf000164_0002
and wherein
R10, R11 and R12 are independently chosen from -H, halogen, -OCH3, -CF3, -OCF3, -CN, C1-C4 alkyl, -NR13R14, -S(O)1nCH3, -CONHR22, -NHCOR23, OR24 and -NHS(O)1nR25; wherein
R13 and R14 are independently chosen from -H and C1-C4 alkyl; R22, R23 and R24 are one or two substituents independently chosen from -H, C1-C4 alkyl, C1-C6 cycloalkyl, aryl, -(CH2)nNR26R27 and -(CH2)nOR28 said C1-C4 alkyl and C1-C6 cycloalkyl being optionally substituted with one or more halogens;
R25 is C1-C4 alkyl;
R26 and R27 are independently chosen from H and C1-C4 alkyl or
R26 and R27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O;
R28 is chosen from H and C1-C4 alkyl; m is 0 , 1 or 2 and n is 1, 2 or 3.
15. A compound, or salt thereof, according to claim 10, wherein:
Figure imgf000164_0003
wherein
R4 is chosen from
Figure imgf000165_0001
and
Figure imgf000165_0002
wherein
R15 and R16 are independently chosen from -H, halogen, -OH, -OCH3,
CF3, -OCF3, -CN and C1-C4 alkyl;
R . 17 is chosen from O and S;
R18 is chosen from CH and N;
R19 and R20 are independently chosen from -H, halogen,
-OCH3, -CF3, -OCF3, -CN, C1-C4 alkyl, and pyridinyl; and is chosen from -H and C1-C4 alkyl.
16. A compound, or salt thereof, according to claim 10, wherein:
R is chosen from
Figure imgf000165_0003
Figure imgf000165_0004
Figure imgf000166_0001
O
1-(CH2)L2-C-N NH S— (CH2)o-2- -(CH2)0_2-NH2 and -
(CH2)3-7-NH2.
17. A compound, or salt thereof, according to claim 10, wherein:
R is chosen from
Figure imgf000166_0002
Figure imgf000166_0003
:— (CH2)0_2-π- -HCH2)o_2-NH2
Figure imgf000166_0004
18. A compound, or salt thereof, according to claim 10, wherein:
Figure imgf000167_0001
wherein
R10, R11 and R12 are independently chosen from -H, halogen, -OCH3,
-CF3, -OCF3, -CN, C1-C4 alkyl, -NR13R14, -S(O)1nCH3, -CONHR22, -NHCOR23,
OR24 and -NHS(O)1nR25; wherein
R13 and R14 are independently chosen from -H and C1-C4 alkyl;
R22, R23 and R24 are one or two substituents independently chosen from -H, C1-C4 alkyl, C1-C6 cycloalkyl, aryl, -(CH2)nNR26R27 and
-(CH2)nOR28 said C1-C4 alkyl and C1-C6 cycloalkyl being optionally substituted with one or more halogens;
R25 is C1-C4 alkyl;
R26 and R27 are independently chosen from H and C1-C4 alkyl or
R26 and R27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O;
R28 is chosen from H and C1-C4 alkyl; m is O , 1 or 2 and n is 1, 2 or 3.
19. A pharmaceutical composition comprising a compound, or salt thereof, according to claim 10, and a pharmaceutically acceptable carrier.
20. A compound, or salt thereof, represented by Formula I,
(I)
Figure imgf000167_0002
wherein: R1 is chosen from C1 -C4 alkyl, phenyl optionally substituted with one or two substituents independently chosen from halogen, OCH3, -CF3, -OCF3 and C1 -C4 alkyl
Figure imgf000168_0001
wherein
R4 is chosen from
Figure imgf000168_0002
Figure imgf000168_0003
wherein
R15 and R16 are independently chosen from -H, halogen, -OH, -OCH3, - CF3, -OCF3, -CN, C1-C4 alkyl, and pyridinyl;
R 17 is chosen from O and S; R 18 is chosen from CH and N;
R19 and R20 are independently chosen from -H, halogen, -OCH3, -CF3, -OCF3, -CN, C1-C4 alkyl, and pyridinyl; and
Z is chosen from -H and C1-C4 alkyl;
R2 is chosen from -(C2-C7 alkyl)-NR5R6, -(C0-C4 alkyl)-R7-R8, and
-(C0-C4 alkyl)-C(0)-(Co-C4 alkyl)-R7-R8, wherein
R7 is chosen from cyclohexyl, phenyl, piperidinyl, pyrrolidinyl, morpholinyl, and piperazinyl; R8 is chosen from -H, -(C0-C4 alkyl)-NR > 5DrR> 6°, and
-C(O)-(C0-C4 alkyl)-NR5R6; and R5 and R6 are independently chosen from -H and -(C1-C4 alkyl); and R2 contains a basic N atom located from 2 to 8 atoms distant from its point of attachment to the purine ring; R3 is chosen from C1-C6 alkyl,
Figure imgf000169_0001
and , wherein
R10, R11 and R12 are independently chosen from -H, halogen, -OCH3, -CF3, -OCF3, -CN, C1-C4 alkyl, -NR13R14, -S(O)1nCH3, -CONHR22, -NHCOR23, OR24 and -NHS(O)1nR25; wherein
R13 and R14 are independently chosen from -H and C1-C4 alkyl; R22, R23 and R24 are one or two substituents independently chosen from -H, C1-C4 alkyl, C1-C6 cycloalkyl, aryl, -(CH2)nNR26R27 and -(CH2)nOR28 said C1-C4 alkyl and C1-C6 cycloalkyl being optionally substituted with one or more halogens;
R25 is C1-C4 alkyl;
R26 and R27 are independently chosen from H and C1-C4 alkyl or
R26 and R27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O;
R28 is chosen from H and C1-C4 alkyl; m is O , 1 or 2 and n is 1, 2 or 3.
21. A compound, or salt thereof, according to claim 20, wherein:
Figure imgf000169_0002
wherein R4 is chosen from
Figure imgf000170_0001
, and
Figure imgf000170_0002
wherein
R15 and R16 are independently chosen from -H, halogen, -OH, -OCH3, CF3, -OCF3, -CN and C1-C4 alkyl; R17 is chosen from O and S; R18 is chosen from CH and N; R19 and R20 are independently chosen from -H, halogen, -OCH3, -CF3, -OCF3, -CN, C1-C4 alkyl, and pyridinyl; and Z is chosen from -H and C1-C4 alkyl.
22. A compound, or salt thereof, according to claim 20, wherein:
Figure imgf000170_0003
R is not
23. A compound, or salt thereof, according to claim 20, wherein:
R2 is chosen from
Figure imgf000170_0004
Figure imgf000170_0005
Figure imgf000171_0001
O
1-(CH2)L2-C-N NH S— (CH2)o-2- -(CH2)0_2-NH2 and -
(CH2)3-7-NH2.
24. A compound, or salt thereof, according to claim 20, wherein:
R is chosen from
Figure imgf000171_0002
Figure imgf000171_0003
:— (CH2)0_2-π- -HCH2)o_2-NH2
Figure imgf000171_0004
25. A compound, or salt thereof, according to claim 20, wherein:
Figure imgf000172_0001
wherein
R10, R11 and R12 are independently chosen from -H, halogen, -OCH3,
-CF3, -OCF3, -CN, C1-C4 alkyl, -NR13R14, -S(O)1nCH3, -CONHR22, -NHCOR23,
OR24 and -NHS(O)1nR25; wherein
R13 and R14 are independently chosen from -H and C1-C4 alkyl;
R22, R23 and R24 are one or two substituents independently chosen from -H, C1-C4 alkyl, C1-C6 cycloalkyl, aryl, -(CH2)nNR26R27 and
-(CH2)nOR28 said C1-C4 alkyl and C1-C6 cycloalkyl being optionally substituted with one or more halogens;
R25 is C1-C4 alkyl;
R26 and R27 are independently chosen from H and C1-C4 alkyl or
R26 and R27 with the N to which they are attached form a 4-7 membered saturated heterocyclic ring optionally comprising an O;
R28 is chosen from H and C1-C4 alkyl; m is O , 1 or 2 and n is 1, 2 or 3.
26. A pharmaceutical composition comprising a compound, or salt thereof, according to claim 20, and a pharmaceutically acceptable carrier.
27. A method of treatment of a T-cell mediated disease comprising administering a therapeutically effective amount of a compound, or salt thereof, of any of claims 1, 10 and 20.
28. The method of claim 27 wherein the T-cell mediated disease is an autoimmune disease.
29. The method of claim 28 wherein the autoimmune disease is rheumatoid arthritis.
30. The method of claim 28 wherein the autoimmune disease is lupus erythematosus.
31. The method of claim 28 wherein the autoimmune disease is multiple sclerosis.
32. The method of claim 27 wherein the T-cell mediated disease is an inflammatory disease.
33. The method of claim 32 wherein the inflammatory disease is asthma.
34. The method of claim 32 wherein the inflammatory disease is inflammatory bowel disease.
35. The method of claim 27 wherein the T-cell mediated disease is transplant rejection.
36. A method of treatment of cancer comprising administering a therapeutically effective amount of a compound, or salt thereof, of any of claims 1, 10 and 20.
37. The method of claim 36 wherein the cancer is gastrointestinal cancer.
38. A method of treatment of diabetes comprising administering a therapeutically effective amount of a compound, or salt thereof, of any of claims 1, 10 and 20.
PCT/US2007/081899 2006-10-20 2007-10-19 Purines as pkc-theta inhibitors WO2008051826A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MX2009004154A MX2009004154A (en) 2006-10-20 2007-10-19 Purines as pkc-theta inhibitors.
CA002666940A CA2666940A1 (en) 2006-10-20 2007-10-19 Purines as pkc-theta inhibitors
AU2007309167A AU2007309167A1 (en) 2006-10-20 2007-10-19 Purines as PKC-theta inhibitors
IN2154CHN2009 IN2009CN02154A (en) 2006-10-20 2007-10-19
BRPI0717435-7A BRPI0717435A2 (en) 2006-10-20 2007-10-19 COMPOUND OR A SALT THEREOF, PHARMACEUTICAL COMPOSITION, AND METHODS OF TREATMENT OF A T-CELL, CANCER AND DIABETIC MEDIATION DISEASE.
JP2009533556A JP2010507581A (en) 2006-10-20 2007-10-19 Purines as PKC-θ inhibitors
EP07844441A EP2078019A2 (en) 2006-10-20 2007-10-19 Purines as pkc-theta inhibitors
US12/445,862 US20110046131A1 (en) 2006-10-20 2007-10-19 Purines as pkc-theta inhibitors
CN2007800418805A CN101657453B (en) 2006-10-20 2007-10-19 Purines as PKC-theta inhibitors
IL198080A IL198080A0 (en) 2006-10-20 2009-04-07 Purines as pkc-theta inhibitors
NO20091597A NO20091597L (en) 2006-10-20 2009-04-22 Purines as PKC-theta inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85339606P 2006-10-20 2006-10-20
US60/853,396 2006-10-20

Publications (2)

Publication Number Publication Date
WO2008051826A2 true WO2008051826A2 (en) 2008-05-02
WO2008051826A3 WO2008051826A3 (en) 2008-10-02

Family

ID=39111415

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/081899 WO2008051826A2 (en) 2006-10-20 2007-10-19 Purines as pkc-theta inhibitors

Country Status (17)

Country Link
US (1) US20110046131A1 (en)
EP (1) EP2078019A2 (en)
JP (1) JP2010507581A (en)
KR (1) KR20090075854A (en)
CN (1) CN101657453B (en)
AU (1) AU2007309167A1 (en)
BR (1) BRPI0717435A2 (en)
CA (1) CA2666940A1 (en)
CO (1) CO6160294A2 (en)
EC (1) ECSP099342A (en)
IL (1) IL198080A0 (en)
IN (1) IN2009CN02154A (en)
MX (1) MX2009004154A (en)
NO (1) NO20091597L (en)
RU (1) RU2009118963A (en)
WO (1) WO2008051826A2 (en)
ZA (1) ZA200902640B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951803B2 (en) * 2006-03-09 2011-05-31 Pharmacopeia, Llc 8-heteroarylpurine MNK2 inhibitors for treating metabolic disorders
WO2011094290A1 (en) * 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
EP2503890A1 (en) * 2009-11-24 2012-10-03 GlaxoSmithKline LLC Azabenzimidazoles as fatty acid synthase inhibitors
WO2013041539A1 (en) * 2011-09-20 2013-03-28 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
US8697708B2 (en) 2010-09-15 2014-04-15 F. Hoffmann-La Roche Ag Azabenzothiazole compounds, compositions and methods of use
WO2016029262A1 (en) * 2014-08-25 2016-03-03 University Of Canberra Compositions for modulating cancer stem cells and uses therefor
WO2019090390A1 (en) * 2017-11-08 2019-05-16 University Of Canberra Immunogenic compositions and uses therefor
JPWO2018143403A1 (en) * 2017-02-03 2019-12-12 国立大学法人東北大学 Heterocyclic compounds

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090281075A1 (en) * 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
EP2038274A2 (en) * 2006-06-23 2009-03-25 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0470543A1 (en) * 1990-08-10 1992-02-12 Dr. Karl Thomae GmbH Heterocyclic imidazoles, remedies containing them and processes for their preparation
EP1043324A1 (en) * 1997-11-12 2000-10-11 Mitsubishi Chemical Corporation Purine derivatives and medicine containing the same as the active ingredient
JP2004217582A (en) * 2003-01-16 2004-08-05 Abbott Japan Co Ltd 9h-purine derivative
WO2006045828A1 (en) * 2004-10-29 2006-05-04 Tibotec Pharmaceuticals Ltd. Hiv inhibiting bicyclic pyrimidine derivatives
WO2006076595A1 (en) * 2005-01-13 2006-07-20 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2006087530A1 (en) * 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
WO2007104053A2 (en) * 2006-03-09 2007-09-13 Pharmacopeia, Inc. 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097062A1 (en) * 2002-05-13 2003-11-27 Merck & Co., Inc. Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0470543A1 (en) * 1990-08-10 1992-02-12 Dr. Karl Thomae GmbH Heterocyclic imidazoles, remedies containing them and processes for their preparation
EP1043324A1 (en) * 1997-11-12 2000-10-11 Mitsubishi Chemical Corporation Purine derivatives and medicine containing the same as the active ingredient
JP2004217582A (en) * 2003-01-16 2004-08-05 Abbott Japan Co Ltd 9h-purine derivative
WO2006045828A1 (en) * 2004-10-29 2006-05-04 Tibotec Pharmaceuticals Ltd. Hiv inhibiting bicyclic pyrimidine derivatives
WO2006076595A1 (en) * 2005-01-13 2006-07-20 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2006087530A1 (en) * 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
WO2007104053A2 (en) * 2006-03-09 2007-09-13 Pharmacopeia, Inc. 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951803B2 (en) * 2006-03-09 2011-05-31 Pharmacopeia, Llc 8-heteroarylpurine MNK2 inhibitors for treating metabolic disorders
US20110230480A1 (en) * 2006-03-09 2011-09-22 Cole Andrew G 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
EP2503890A1 (en) * 2009-11-24 2012-10-03 GlaxoSmithKline LLC Azabenzimidazoles as fatty acid synthase inhibitors
JP2013512245A (en) * 2009-11-24 2013-04-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Azabenzimidazole as a fatty acid synthase inhibitor
EP2503890A4 (en) * 2009-11-24 2013-05-15 Glaxosmithkline Llc Azabenzimidazoles as fatty acid synthase inhibitors
WO2011094290A1 (en) * 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
CN102869664A (en) * 2010-01-27 2013-01-09 沃泰克斯药物股份有限公司 Pyrazolopyrimidine kinase inhibitors
US8809335B2 (en) 2010-01-27 2014-08-19 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
JP2013518114A (en) * 2010-01-27 2013-05-20 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrazolopyrimidine kinase inhibitor
US8697708B2 (en) 2010-09-15 2014-04-15 F. Hoffmann-La Roche Ag Azabenzothiazole compounds, compositions and methods of use
US20140206702A1 (en) * 2011-09-20 2014-07-24 Genentech, Inc. Imidazopyridine compounds, compositions and methods of use
WO2013041539A1 (en) * 2011-09-20 2013-03-28 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
WO2016029262A1 (en) * 2014-08-25 2016-03-03 University Of Canberra Compositions for modulating cancer stem cells and uses therefor
US10485772B2 (en) 2014-08-25 2019-11-26 EpiAxis Therapeutics Pty Ltd. Compositions for modulating cancer stem cells and uses therefor
AU2015309686B2 (en) * 2014-08-25 2020-05-14 Epiaxis Therapeutics Pty Ltd Compositions for modulating cancer stem cells and uses therefor
JPWO2018143403A1 (en) * 2017-02-03 2019-12-12 国立大学法人東北大学 Heterocyclic compounds
JP7161760B2 (en) 2017-02-03 2022-10-27 国立大学法人東北大学 heterocyclic compound
US11986480B2 (en) 2017-02-03 2024-05-21 Tohoku University Heterocyclic compound
WO2019090390A1 (en) * 2017-11-08 2019-05-16 University Of Canberra Immunogenic compositions and uses therefor
AU2018363880B2 (en) * 2017-11-08 2022-04-07 Epiaxis Therapeutics Pty Ltd Immunogenic compositions and uses therefor

Also Published As

Publication number Publication date
WO2008051826A3 (en) 2008-10-02
IL198080A0 (en) 2009-12-24
CN101657453A (en) 2010-02-24
JP2010507581A (en) 2010-03-11
ECSP099342A (en) 2009-06-30
BRPI0717435A2 (en) 2014-03-18
NO20091597L (en) 2009-07-14
CN101657453B (en) 2013-06-12
US20110046131A1 (en) 2011-02-24
ZA200902640B (en) 2010-05-26
CA2666940A1 (en) 2008-05-02
EP2078019A2 (en) 2009-07-15
MX2009004154A (en) 2009-09-09
KR20090075854A (en) 2009-07-09
CO6160294A2 (en) 2010-05-20
IN2009CN02154A (en) 2015-08-07
RU2009118963A (en) 2010-11-27
AU2007309167A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
EP2078019A2 (en) Purines as pkc-theta inhibitors
US7989459B2 (en) Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
JP6742323B2 (en) JAK inhibitor
KR102531036B1 (en) Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
US7902187B2 (en) 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US20090281075A1 (en) Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US7312330B2 (en) Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
WO2009062059A2 (en) Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
WO2008143674A1 (en) Purinones and 1h-imidazopyridinones as pkc-theta inhibitors
EP3377496A1 (en) Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
KR102477063B1 (en) Heterobicyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
EP3541817B1 (en) Imidazopyridazine modulators of il-12, il-23 and/or ifn-alpha
KR20070042568A (en) Chemical compounds
AU2008304417A1 (en) Polo-like kinase inhibitors
HUE034807T2 (en) Novel quinoline-substituted compound
JP2008531716A (en) Compound
WO2014151630A2 (en) Compounds and compositions for the treatment of parasitic diseases
CN114206853A (en) Targeted protein degradation of PARP14 for therapy
US20080146536A1 (en) 2-Aminoimidazopyridines for treating neurodegenerative diseases
TW201741303A (en) Pyrimidine derivative, method for preparing same and use thereof in medicine
WO2015144021A1 (en) Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof
US20110071130A1 (en) 2-aminobenzimidazoles for treating neurodegenerative diseases
EP4100008A1 (en) Pyrrolo [2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss
JP6522502B2 (en) Wnt signal inhibitor
CN117015528A (en) Indole derivatives as kinase inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780041880.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07844441

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 198080

Country of ref document: IL

Ref document number: 12009500659

Country of ref document: PH

Ref document number: 2007844441

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 576198

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2666940

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009533556

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007309167

Country of ref document: AU

Ref document number: MX/A/2009/004154

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 09039704

Country of ref document: CO

Ref document number: 2154/CHENP/2009

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020097009128

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009118963

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2007309167

Country of ref document: AU

Date of ref document: 20071019

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12445862

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0717435

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090417